<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease - Khanna, R - 2016 | Cochrane Library</title> <meta content="Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease - Khanna, R - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010642.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease - Khanna, R - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010642.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010642.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease" name="citation_title"/> <meta content="Reena Khanna" name="citation_author"/> <meta content="Sigrid A Nelson" name="citation_author"/> <meta content="Robarts Clinical Trials" name="citation_author_institution"/> <meta content="Brian G Feagan" name="citation_author"/> <meta content="brian.feagan@robartsinc.com" name="citation_author_email"/> <meta content="Geert D'Haens" name="citation_author"/> <meta content="William J Sandborn" name="citation_author"/> <meta content="GY Zou" name="citation_author"/> <meta content="John K MacDonald" name="citation_author"/> <meta content="Claire E Parker" name="citation_author"/> <meta content="Robarts Clinical Trials" name="citation_author_institution"/> <meta content="Vipul Jairath" name="citation_author"/> <meta content="Barrett G Levesque" name="citation_author"/> <meta content="Robarts Clinical Trials" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD010642.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/08/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010642.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010642.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010642.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Endoscopy, Gastrointestinal; *Severity of Illness Index; Blood Sedimentation; C‐Reactive Protein [analysis]; Cohort Studies; Crohn Disease [*pathology]; Feces [chemistry]; Randomized Controlled Trials as Topic; Reproducibility of Results" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010642.pub2&amp;doi=10.1002/14651858.CD010642.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="na56WA6j";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010642\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010642\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","pl","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010642.pub2",title:"Endoscopic scoring indices for evaluation of disease activity in Crohn\\u2019s disease",firstPublishedDate:"Aug 8, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010642.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010642.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010642.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010642.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010642.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010642.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010642.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010642.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010642.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010642.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2867 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010642.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-sec-0058"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-sec-0025"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-sec-0026"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-sec-0052"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/appendices#CD010642-sec-0061"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Methodology</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information#CD010642-cr-0002">Reena Khanna</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information#CD010642-cr-0003">Sigrid A Nelson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information#CD010642-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Brian G Feagan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information#CD010642-cr-0005">Geert D'Haens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information#CD010642-cr-0006">William J Sandborn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information#CD010642-cr-0007">GY Zou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information#CD010642-cr-0008">John K MacDonald</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information#CD010642-cr-0009">Claire E Parker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information#CD010642-cr-0010">Vipul Jairath</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information#CD010642-cr-0011">Barrett G Levesque</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information/en#CD010642-sec-0064">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 August 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010642.pub2">https://doi.org/10.1002/14651858.CD010642.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010642-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010642-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010642-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010642-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010642-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010642-abs-0001" lang="en"> <section id="CD010642-sec-0001"> <h3 class="title" id="CD010642-sec-0001">Background</h3> <p>Endoscopic assessment of mucosal disease activity is widely used to determine eligibility and response to therapy in clinical trials of treatment for Crohn’s disease. However, the operating properties of the currently available endoscopic indices remain unclear. </p> </section> <section id="CD010642-sec-0002"> <h3 class="title" id="CD010642-sec-0002">Objectives</h3> <p>A systematic review was undertaken to evaluate the development and operating characteristics of the Crohn’s Disease Endoscopic Index of Severity (CDEIS) and Simple Endoscopic Scale for Crohn’s Disease (SES‐CD). </p> </section> <section id="CD010642-sec-0003"> <h3 class="title" id="CD010642-sec-0003">Search methods</h3> <p>Electronic searches of the MEDLINE (1966 to December 2015), EMBASE (1980 to December 2015), and Cochrane CENTRAL Register of Controlled Trials (Issue 12, 2015) databases were supplemented by manual reviews of reference listings and conference proceedings (Digestive Disease Week, United European Gastroenterology Week, European Crohn’s and Colitis Organization). </p> </section> <section id="CD010642-sec-0004"> <h3 class="title" id="CD010642-sec-0004">Selection criteria</h3> <p>Any study design (e.g. randomized controlled trials, cohort studies, case series) that evaluated either or both the CDEIS or SES‐CD in patients with Crohn’s disease was considered for inclusion. Eligible participants were adult patients (&gt; 16 years), diagnosed with Crohn’s disease using conventional clinical, radiographic, and endoscopic criteria. </p> </section> <section id="CD010642-sec-0005"> <h3 class="title" id="CD010642-sec-0005">Data collection and analysis</h3> <p>Two authors (RK, JKM) independently reviewed the titles and abstracts of the studies identified from the literature search. The full texts of potentially relevant citations were reviewed for inclusion and the study investigators were contacted to clarify any unclear data. Any disagreements were resolved by discussion and consensus with a third author. A standardized form was used to assess eligibility of trials for inclusion in the study and for data extraction. </p> <p>Two authors independently extracted and recorded data (RK, SAN). The number of patients enrolled; number of patients per treatment arm; patient characteristics including age and gender distribution; endoscopic index; and outcomes such as intra‐rater reliability, inter‐rater reliability responsiveness, validity, feasibility, construct validity, and criterion validity were recorded for each trial. </p> </section> <section id="CD010642-sec-0006"> <h3 class="title" id="CD010642-sec-0006">Main results</h3> <p>Forty‐three reports of 30 studies fulfilled the inclusion criteria.</p> <p>For the SES‐CD, inter‐rater reliability was assessed in four studies. In the development study for the SES‐CD (<a href="http://Daperno 2004" target="_blank">Daperno 2004</a>), the overall ICC (0.9815, 95% CI 0.9705 to 0.9884) and the kappa for the regions is high; however the paired raters were in the same room which introduces the potential for bias. </p> <p>For the CDEIS, inter‐rater reliability was assessed in six studies. <a href="http://Daperno 2014" target="_blank">Daperno 2014</a> reported that the ICC for the CDEIS was 0.985 (95% CI 0.939‐1.000) for average measures of video score and was 0.835 (95% CI 0.540‐0.995) for single measures of video score. </p> <p>With respect to validity, correlation between the CDEIS and clinical measures, including C‐reactive protein (CRP) and erythrocyte sedimentation rate (ESR), was also reported. The estimates of correlation with CRP were r = 0.521 (<a href="http://Sipponen 2010b" target="_blank">Sipponen 2010b</a>), r = 0.553 (<a href="http://Sipponen 2008a" target="_blank">Sipponen 2008a</a>) and r = 0.608 (<a href="http://Sipponen 2008c" target="_blank">Sipponen 2008c</a>). For the SES‐CD, the corresponding values for correlation with CRP ranged from r = 0.46 (<a href="http://Jones 2008" target="_blank">Jones 2008</a>) to r = 0.68 (<a href="http://Green 2011" target="_blank">Green 2011</a>). </p> <p>Responsiveness data for the CDEIS were available in nine studies. Seven studies demonstrated statistically significant decreases in the CDEIS score after administration of a treatment of known efficacy. Minimal responsiveness data were available for the SES‐CD. <a href="http://Sipponen 2010a" target="_blank">Sipponen 2010a</a> and <a href="http://Sipponen 2010b" target="_blank">Sipponen 2010b</a> demonstrated statistically significant changes in the SES‐CD score after subjects were administered a treatment of known efficacy. </p> <p>No studies were identified that explicitly evaluated the feasibility for either the SES‐CD or the CDEIS. The SES‐CD requires fewer calculations and may therefore be easier to use than the CDEIS. </p> </section> <section id="CD010642-sec-0007"> <h3 class="title" id="CD010642-sec-0007">Authors' conclusions</h3> <p>Although they are used in clinical trials, the CDEIS and SES‐CD remain incompletely validated. Future research is required to determine the operating properties and to define the optimal index. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010642-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010642-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010642-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010642-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010642-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010642-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/pl#CD010642-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010642-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010642-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010642-abs-0003" lang="en"> <h3>Endoscopic scoring indices for evaluation of disease activity in Crohn's disease</h3> <p><b>What is Crohn's disease?</b> <br/> Crohn's disease is a long‐term (chronic) inflammatory bowel disease characterized by pain (abdominal cramping), tiredness, diarrhea and weight loss. When people with Crohn's disease are experiencing symptoms the disease is said to be "active" and when symptoms stop this is called "remission". </p> <p><b>What is an endoscopic scoring index?</b> <br/> An endoscopic scoring index measures disease activity based on what a doctor sees during endoscopy. An endoscopy is a non‐surgical procedure used to view the digestive tract using a camera. The doctor who performs the endoscopy can rate disease activity using the index, or this can be done by another off‐site doctor if a video of the procedure was recorded. </p> <p>The most commonly used endoscopic scoring indices are the Crohn's Disease Endoscopic Index of Severity (CDEIS) and the Simple Endoscopic Score for Crohn's Disease (SES‐CD). </p> <p><b>What did the researchers investigate?</b> <br/> It is important that endoscopic scoring indices are valid, meaning that they accurately measure what they are supposed to measure. The researchers investigated whether studies have assessed the validity of the CDEIS and/or the SES‐CD. </p> <p><b>What did the researchers find?</b> </p> <p>The researchers found that neither the CDEIS nor the SES‐CD has been fully validated.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010642-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010642-sec-0058"></div> <h3 class="title" id="CD010642-sec-0059">Implication for methodological research</h3> <section id="CD010642-sec-0059"> <p>There is an imminent need for additional validation studies to define the optimal endoscopic index for use in clinical trials of CD. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010642-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010642-sec-0022"></div> <section id="CD010642-sec-0023"> <h3 class="title" id="CD010642-sec-0023">Description of the problem or issue</h3> <p>Crohn’s disease (CD) is a chronic inflammatory disease of unknown etiology that can affect any part of the gastrointestinal tract. Clinically, the disease presents with diarrhea, abdominal pain, fatigue, and weight loss and is characterized a relapsing‐remitting course. Endoscopic findings include mucosal edema, erythema granularity, friability, and ulcers. Disease activity may be classified as mild, moderate, severe, or fulminant based on combined clinical and endoscopic assessments. Although CD may involve any part of the gastrointestinal tract, approximately 20% of patients have isolated colonic involvement, 30% have disease limited to the small bowel, and 50% of patients have involvement of both the ileum and the colon. </p> <p>Several endoscopic and clinical indices have been developed to evaluate CD activity in clinical trials. It is now apparent that a poor correlation exits between symptoms, as measured by an instrument such as the Crohn’s Disease Activity Index (CDAI), and endoscopic measures (<a href="./references#CD010642-bbs2-0040" title="CellierC , SahmoudT , FroguelE , AdenisA , BelaicheJ , BretagneJF , et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. Gut1994;35:231‐5. ">Cellier 1994</a>; <a href="./references#CD010642-bbs2-0045" title="RegueiroM , KipKE , SchrautW , BaidooL , SepulvedaAR , et al. Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflammatory Bowel Diseases2011;17(1):118‐26. ">Regueiro 2011</a>). Recently, increased importance has been placed on the use of endoscopic instruments as outcome measures in clinical research, since they are potentially more objective than symptom‐based indices (<a href="./references#CD010642-bbs2-0042" title="U.S. Food and Drug Administration (FDA) Workshop: Gastroenterology regulatory endpoints and the advancement of therapeutics (transcript). https://www.regulations.gov/#!documentDetail;D=FDA‐2013‐N‐0001‐0130 (Accessed March 30, 2016). ">FDA 2013</a>). Therefore, the operating properties of these endoscopic indices must be clearly defined. In particular, an endoscopic index must be valid (it must measure the outcome that it is intended to assess); responsive (it must detect a meaningful change in health status); and reliable (consistent results are obtained in patients whose clinical status has remained stable) (<a href="./references#CD010642-bbs2-0044" title="KirshnerB , GuyattG . A methodological framework for assessing health indices. Journal of Chronic Diseases1985;38(1):27‐36. ">Kirshner 1985</a>). Furthermore, an ideal instrument should be highly feasible to use in the setting of a clinical trial. Currently, the Crohn's Disease Endoscopic Index of Severity (CDEIS) (<a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>) and the Simple Endoscopic Score for Crohn's Disease (SES‐CD) (<a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>) are the most commonly used indices to assess eligibility and response to therapy in clinical trials. </p> <p>The CDEIS assesses five segments of the intestine: rectum, sigmoid and left colon, traverse colon, right colon, and ileum (<a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>). For each colonic segment, the presence of deep and superficial ulceration, the percentage of ulcerated surface and the percentage of surface involved by CD are measured on a 10 centimetre visual analogue scale. Additionally, the presence of ulcerated and non‐ulcerated stenoses are assessed. These items are weighted and summed to yield a total score that ranges from 0 to 44. Higher scores indicate more severe disease.  </p> <p>The SES‐CD evaluates four endoscopic items (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis). Each item is scored by segment on a scale from zero to three (<a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>). The maximum SES‐CD score is 56, with higher scores indicating more severe disease. </p> </section> <section id="CD010642-sec-0024"> <h3 class="title" id="CD010642-sec-0024">Why it is important to do this review</h3> <p>There are few data available on the operating properties of these two indices despite their widespread use as outcomes in clinical trials. This review will evaluate the relative merits of the two indices and identify areas where further validation of the CDEIS and SES‐CD is required. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010642-sec-0025" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010642-sec-0025"></div> <p>The primary objective is to systematically review the current literature describing the development and operating characteristics of endoscopic disease activity indices used to evaluate the activity of Crohn's disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010642-sec-0026" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010642-sec-0026"></div> <section id="CD010642-sec-0027"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010642-sec-0028"> <h4 class="title">Types of studies</h4> <p>Any study design (e.g. randomized controlled trials, cohort studies, case series) that evaluates either the SES‐CD or CDEIS or both in patients with Crohn's disease was considered for inclusion. Study subjects included adult patients (&gt; 16 years), diagnosed with Crohn's disease using conventional clinical, radiographic, and endoscopic criteria. </p> </section> <section id="CD010642-sec-0029"> <h4 class="title">Types of data</h4> <p>Endoscopic scoring data obtained from eligible studies were considered for inclusion.</p> </section> <section id="CD010642-sec-0030"> <h4 class="title">Types of methods</h4> <p>The methods used to construct and validate the endoscopic indices (e.g. reliability, validity, responsiveness and feasibility) were examined in detail and described for each eligible study. We also reported the number of endoscopists who scored the indices in each study and whether they were blinded to other raters' scores. </p> </section> <section id="CD010642-sec-0031"> <h4 class="title">Types of outcome measures</h4> <p><b>Reliability:</b> For each study reliability was assessed by measuring intra‐rater reliability, inter‐rater reliability or internal consistency. Intra‐ and inter‐rater reliability were assessed by using the interclass correlation coefficient (ICC) for repeat assessments made by the same rater, and for assessments made by different raters. </p> <p><b>Validity:</b> Validity was broadly defined as evidence that variations in Crohn's disease severity causally produce variations in the endoscopic indices' measurement outcomes. Studies were assessed to determine whether content validity, criterion validity, or construct validity for endoscopic index scores in specific clinical situations were reported. </p> <p>A Crohn's disease endoscopic index demonstrates content validity if the components of the index are sufficient to measure disease activity. Content validation was generally based on qualitative assessment. For example, evidence of content validity includes expert panel opinion on face validity, or a systematic review of the literature supporting the development of an endoscopic index. </p> <p>Criterion validity was demonstrated if the index scores are an adequate reflection of true Crohn's disease activity as assessed by a gold standard. The lack of a single gold standard for Crohn's disease activity is a limitation of these assessments. Studies of predictive criterion validity will be reported which compare whether the score predicts true Crohn's disease activity as measured by objective measures of inflammation including C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), fecal lactoferrin, or fecal calprotectin. Studies of criterion validity which compare endoscopic scores with future sequelae, such as surgery or disability will also be reported. Statistical parameters for agreement between the “EI and gold standards” were assessed (i.e., sensitivity or specificity, receiver operating characteristic (ROC) curve, area under the receiver operating characteristic curve (AUC), mean difference, weighed kappa, Spearman's r squared, and the ICC). </p> <p>Studies that assess construct validity of the endoscopic indices, which acknowledge the limitation of the lack of a gold standard for disease activity and assess whether the endoscopic indices are consistent with other hypotheses of true disease activity were included. Studies of construct validity of the endoscopic index were reported if they measured the correlation between the scores obtained from endoscopic and clinical indices, including the physician's global assessment of disease activity. The minimal clinically important difference (MCID) and appropriate cut‐off values to determine active and inactive disease states, clinical response, and clinical remission were examined. </p> <p><b>Responsiveness:</b> Responsiveness, the ability of the index to detect change, was determined by assessing changes in the endoscopic index scores following a treatment of known efficacy. Responsiveness was quantified using indicators of effect size (<a href="./references#CD010642-bbs2-0046" title="ZouGY . Quantifying responsiveness of quality of life measures without an external criterion. Quality of Life Research2005;14(6):1545‐52. ">Zou 2005</a>), or with the use of ROC curves to describe how well score changes can distinguish improved patients from those without response (<a href="./references#CD010642-bbs2-0041" title="DeyoRA , DiehrP , PatrickDL . Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Controlled Clinical Trials1991;12(4 Suppl):142S‐158S. ">Deyo 1991</a>). </p> <p><b>Feasibility:</b> Feasibility was assessed as the raters' evaluation of the ease of administration and time required for scoring. </p> </section> </section> <section id="CD010642-sec-0032"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010642-sec-0033"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases from inception to 1 December 2015:</p> <p>1. MEDLINE;</p> <p>2. EMBASE;</p> <p>3. The Cochrane LIbrary (CENTRAL); and</p> <p>4. The Cochrane IBD Group Specialized Register.</p> <p>The search strategies for each database are documented in <a href="./appendices#CD010642-sec-0062">Appendix 1</a>. </p> </section> <section id="CD010642-sec-0034"> <h4 class="title">Searching other resources</h4> <p>We also searched major gastroenterology meetings (2000 to present) including:</p> <p>1. Digestive Disease Week (DDW);</p> <p>2. United European Gastroenterology Week (UEGW); and</p> <p>3. European Crohn's and Colitis Organization (ECCO).</p> <p>Reference lists from retrieved articles were scanned to identify additional citations that may have been overlooked by the database search. </p> </section> </section> <section id="CD010642-sec-0035"> <h3 class="title" id="CD010642-sec-0035">Data collection and analysis</h3> <section id="CD010642-sec-0036"> <h4 class="title">Selection of studies</h4> <p>Two authors (RK and JKM) independently reviewed the titles and abstracts of the studies identified from the literature search. The full text of potentially relevant citations were reviewed for inclusion and the study investigators were contacted to clarify any unclear data, as required. Any disagreements were resolved by discussion and consensus with a third author (BGF). </p> <p>A standardized form was used to assess eligibility of trials for inclusion in the study. Each item on the form was scored as yes, no or unclear. The following items were assessed: </p> <p>a) Diagnosis of Crohn's disease; and</p> <p>b) Assessment of CDEIS or SES‐CD. </p> </section> <section id="CD010642-sec-0037"> <h4 class="title">Data extraction and management</h4> <p>A standardized form was used to extract information from selected studies. Two authors (RK, SAN) independently extracted and recorded data. The following data were recorded from each eligible study:  </p> <p>a) Number of patients enrolled, number of patients per treatment arm;</p> <p>b) Patient characteristics: age and gender distribution;</p> <p>c) Endoscopic index: CDEIS or SES‐CD;</p> <p>d) Thresholds in the CDEIS or SES‐CD associated with clinical response or remission; and </p> <p>e) Outcomes: intra‐rater reliability; inter‐rater reliability; responsiveness; validity; feasibility; construct validity; criterion validity, and the MCID. </p> </section> <section id="CD010642-sec-0038"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the following criteria to appraise the risk of bias of included studies:</p> <p> <ul id="CD010642-list-0001"> <li> <p>Blinding to clinical information</p> </li> <li> <p>Independent observation by endoscopists</p> </li> </ul> </p> <p>Blinding to clinical information such as symptoms, physical examination, or laboratory information is important for objective assessment of endoscopic data (<a href="./references#CD010642-bbs2-0043" title="FeaganBG , SandbornWJ , D'HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149‐57. ">Feagan 2013</a>). Furthermore, independent observation is essential to ensure confidence in the inter‐rater reliability coefficients. </p> <p>We also assessed the methodological quality of the included studies using the COSMIN (COnsensus‐based Standards for the selection of health Measurement INstrumets) checklist. The checklist consists of 10 properties: internal consistency, reliability, measurement error, content validity, structural validity (factor analysis), hypothesis testing, cross‐cultural validity, criterion validity, responsiveness to change and interpretability. Each property is rated on a four‐point scale (1 = poor, 2 = fair, 3 = good, or 4 = excellent). The overall score for the assessment of an individual measurement property is obtained by taking the lowest score for any of the items in the property box (i.e. if any item in the property box is scored as "poor" then the overall score for that property is "poor"). </p> </section> <section id="CD010642-sec-0039"> <h4 class="title">Measures of the effect of the methods</h4> <p>Descriptive statistics were used to report the validation of outcome data. Frequencies and percentages were shown for categorical variables. </p> </section> <section id="CD010642-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>Where possible, authors were contacted to provide any missing information.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010642-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010642-sec-0041"></div> <section id="CD010642-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD010642-sec-0043"> <h4 class="title">Results of the search</h4> <p>The literature search conducted on 1 December 2015 identified 4334 records. After duplicates were removed, a total of 3039 records were screened for inclusion. Of these, 55 reports were selected for full text review. Ten reports of seven studies were excluded (see <a href="./references#CD010642-sec-0068" title="">Characteristics of excluded studies</a>), leaving 45 reports of 31 studies that met the pre‐defined inclusion criteria (see <a href="#CD010642-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010642-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010642-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010642.pub2/media/CDSR/CD010642/image_n/nCD010642-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010642-sec-0044"> <h4 class="title">Included studies</h4> <p>Thirty studies (43 reports) were completed at the time of screening and reported validation results (<a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a>; <a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a>; <a href="./references#CD010642-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. ">Colombel 2003</a>; <a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>; <a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a>; <a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a>; <a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a>; <a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a>; <a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a>; <a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a>; <a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a>; <a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a>; <a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a>; <a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a>; <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>; <a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a>; <a href="./references#CD010642-bbs2-0018" title="ReinischW , RutgeertsPJ , PanaccioneR , D'HaensGR , ThakkarR , YuAP , et al. Prediction of long‐term clinical remission for adalimumab‐treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES‐CD. Gastroenterology2010;138(5 Suppl 1):S8. ">Reinisch 2010</a>; <a href="./references#CD010642-bbs2-0019" title="RimolaJ , OrdasI , RodriguezS , Garcia‐BoschO , AceitunoM , LlachJ , et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflammatory Bowel Diseases2011;17(8):1759‐68. ">Rimola 2011</a>; <a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a>; <a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a>; <a href="./references#CD010642-bbs2-0022" title="RutgeertsPJ , ReinischW , ThakkarR , WuEQ , KaltenboeckA , YangM , et al. Early mucosal healing status predicts long‐term clinical benefits for adalimumab‐treated patients with moderate to severe Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S85. RutgeertsPJ , ThakkarR , WuEQ , KaltenboeckA , YangM , MulaniP , et al. Quality‐of‐life benefits for adalimumab‐treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status. Gastroenterology2010;138(5 Suppl 1):S320. ">Rutgeerts 2010</a>; <a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a>; <a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a>; <a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a>; <a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a>; <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>; <a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a>; <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>; <a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a>). One study (two reports) was ongoing and reported preliminary results but no validation results (<a href="./references#CD010642-bbs2-0039" title="BuissonA , FilippiJ , AmiotA , CadiotG , AllezM , MarteauPR , et al. Definitions of the endoscopic lesions in Crohn's disease: reproductibility study and GETAID expert consensus. Gastroenterology2015;148(4 Suppl 1):S445‐6. BuissonA , FilippiJ , AmiotA , CadiotG , AllezM , MarteauPR , et al. Definitions of the endoscopic lesions in Crohn's disease: reproductibility study and GETAID expert consensus. Journal of Crohn's and Colitis2015;9:S175‐6. ">Buisson 2015</a>). </p> <p>Of the 30 included studies, 10 evaluated the SES‐CD (<a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a>; <a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a>; <a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a>; <a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a>; <a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a>; <a href="./references#CD010642-bbs2-0018" title="ReinischW , RutgeertsPJ , PanaccioneR , D'HaensGR , ThakkarR , YuAP , et al. Prediction of long‐term clinical remission for adalimumab‐treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES‐CD. Gastroenterology2010;138(5 Suppl 1):S8. ">Reinisch 2010</a>; <a href="./references#CD010642-bbs2-0022" title="RutgeertsPJ , ReinischW , ThakkarR , WuEQ , KaltenboeckA , YangM , et al. Early mucosal healing status predicts long‐term clinical benefits for adalimumab‐treated patients with moderate to severe Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S85. RutgeertsPJ , ThakkarR , WuEQ , KaltenboeckA , YangM , MulaniP , et al. Quality‐of‐life benefits for adalimumab‐treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status. Gastroenterology2010;138(5 Suppl 1):S320. ">Rutgeerts 2010</a>; <a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a>; <a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a>; <a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a>), 12 evaluated the CDEIS (<a href="./references#CD010642-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. ">Colombel 2003</a>; <a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a>; <a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a>; <a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a>; <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>; <a href="./references#CD010642-bbs2-0019" title="RimolaJ , OrdasI , RodriguezS , Garcia‐BoschO , AceitunoM , LlachJ , et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflammatory Bowel Diseases2011;17(8):1759‐68. ">Rimola 2011</a>; <a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a>; <a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a>; <a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a>; <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>; <a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a>), and 8 evaluated both the SES‐CD and CDEIS (<a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>; <a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a>; <a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a>; <a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a>; <a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a>; <a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a>; <a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a>; <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>). See <a href="#CD010642-tbl-0001">Table 1</a>. </p> <div class="table" id="CD010642-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of Included Studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of Readers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of CD</b> </p> <p><b>Patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of Endoscopies</b> </p> <p><b>and Reviews</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Material</b> </p> <p><b>Reviewed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Independent</b> </p> <p><b>Review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinded</b> </p> <p><b>Review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Operating Properties Assessed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210 colonoscopies</p> <p>Each SES‐CD scored by at least 2 gastroenterologists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supervised colonoscopies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> <p>Fecal calprotectin blinded</p> <p>but not other lab or</p> <p>clinical data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balloon enteroscopy,</p> <p>from medical charts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. ">Colombel 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (AZA or placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (Placebo: 8,<br/> IFX: 22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (30 pre, 30 post)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy (also recorded)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>a) Development of SES‐CD: 70 patients</p> <p>(endoscopist paired with observer</p> <p>for 35 of 70)<br/> b) Validation of SES‐CD: </p> <p>121 patients</p> <p>(endoscopist paired with second observer for 36 of 121)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy and live video feed:<br/> local endoscopist (70 +121), </p> <p>second observer from a television</p> <p>monitor (35 + 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliability; criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Videos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliability</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 videos (24 pre, 24 post)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Videos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172 (120 with high</p> <p>baseline CRP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>344 (172 pre, 172 post)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Videos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (15 with high HBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chart review of colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 central readers,</p> <p>1 local</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 (44 with paired</p> <p>endoscopy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88 (44 pre, 44 post)</p> <p>2 central reviews per endoscopy</p> <p>133 videos with consent (49 at baseline, 51 at week 10, 33 at week 54)</p> <p>Each video was read by a pair of central readers (266 reads)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Videos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliability; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 patients (10 infliximab,</p> <p>10 adalimumab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 scopes (20 pre, 20 post)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>157 with SES‐CD scored</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 central readers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 central readers performed 3 independent measurements for each of the 50 videos</p> <p>Each of the 50 videos was replicated twice to create 150 samples that were read by the four readers in random order </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Videos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliability; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 patients (SES‐CD)</p> <p>46 patients (CDEIS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 colonoscopies performed; 89 were complete ileocolonoscopies</p> <p>46 colonoscopies performed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>a) 75</p> <p>b) 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>a) Reproducibility=75 patients (75 colonoscopies read twice = 150 reviews)</p> <p>b) Responsiveness=54 patients (103 colonoscopies read once)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy‐ one reader performing the</p> <p>procedure,</p> <p>one viewing through teaching tube</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliability; construct validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 8 (local)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183 (109 Infliximab,</p> <p>74 adalimumab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0018" title="ReinischW , RutgeertsPJ , PanaccioneR , D'HaensGR , ThakkarR , YuAP , et al. Prediction of long‐term clinical remission for adalimumab‐treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES‐CD. Gastroenterology2010;138(5 Suppl 1):S8. ">Reinisch 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186 with Baseline, week 12 and week 24 results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0019" title="RimolaJ , OrdasI , RodriguezS , Garcia‐BoschO , AceitunoM , LlachJ , et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflammatory Bowel Diseases2011;17(8):1759‐68. ">Rimola 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (single review but both reviewers involved: one performed examination</p> <p>and other annotated findings)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 patients (24 placebo,</p> <p>19 infliximab 5mg/kg, 23 infliximab 10 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>198 (baseline, Wk 10, Wk 54 for</p> <p>66 patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Construct validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99 (75 evaluated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231 (99 baseline, 74 week 10,</p> <p>58 week 54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy ‐ by local endoscopist,</p> <p>video ‐ by single reader for</p> <p>mucosal healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0022" title="RutgeertsPJ , ReinischW , ThakkarR , WuEQ , KaltenboeckA , YangM , et al. Early mucosal healing status predicts long‐term clinical benefits for adalimumab‐treated patients with moderate to severe Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S85. RutgeertsPJ , ThakkarR , WuEQ , KaltenboeckA , YangM , MulaniP , et al. Quality‐of‐life benefits for adalimumab‐treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status. Gastroenterology2010;138(5 Suppl 1):S320. ">Rutgeerts 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180 (baseline, week 12 and week 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity;</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 blinded central reader</p> <p>up to 2 designated endoscopists per site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline: 129</p> <p>Week 12: 122</p> <p>Week 52: 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline: 129</p> <p>Week 12: 122</p> <p>Week 52: 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy and videos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliability;</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122 (plus 43 healthy controls)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140 colonoscopies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106 procedures (25 patients</p> <p>with 2 scopes, 2 patients with 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87 ileocolonoscopy in 61 patients</p> <p>(37 scoped once, 22 twice, 2 three times)</p> <p>Single read of each</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>? (blind to fecal assay results but unclear if they were aware of CDAI score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (14 infliximab,</p> <p>1 adalimumab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 colonoscopies (baseline and week 12, or week 10 for</p> <p>adalimumab patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (19 at baseline and 19 at 4‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86,</p> <p>32 with second endoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 baseline, 32 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 double balloon enteroscopies</p> <p>2 endoscopists reviewed each by video</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Video</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity</p> </td> </tr> </tbody> </table> </div> <p>Various thresholds were used to define response and remission using the SES‐CD or CDEIS in the included studies. A summary of the thresholds used by each study is provided in <a href="#CD010642-tbl-0002">Table 2</a>. </p> <div class="table" id="CD010642-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Scoring Index Cut‐offs</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cut‐off</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outocme</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cut‐off</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission 0‐2;</p> <p>Mild 3‐6;</p> <p>Moderate 7‐15;</p> <p>Severe &gt; 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Musocal healing 0‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease of at least 50%</p> <p>and at least 5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease of at least 50%</p> <p>and at least 5 points</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease of at least 50%</p> <p>and at least 5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease of at least 50%</p> <p>and at least 5 points</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission: &lt; 6</p> <p>Complete Remission: &lt; 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS decrease of &gt; 5 points</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cutoff &gt; 7, predicted by</p> <p>biomarkers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission 0‐2;</p> <p>Mild 3‐6;</p> <p>Moderate 7‐15;</p> <p>Severe &gt; 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0018" title="ReinischW , RutgeertsPJ , PanaccioneR , D'HaensGR , ThakkarR , YuAP , et al. Prediction of long‐term clinical remission for adalimumab‐treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES‐CD. Gastroenterology2010;138(5 Suppl 1):S8. ">Reinisch 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cutoff &gt; 5 for</p> <p>predicting future remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inactive:0‐3,</p> <p>Mild 4‐10,</p> <p>Moderate 11‐19,</p> <p>High &gt;=20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inactive:0‐2,</p> <p>Mild 3‐9,</p> <p>Moderate 9‐12, Severe &gt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suggested cutoff 3 for inactive,</p> <p>but still unsettled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inactive:0‐2,</p> <p>Mild 3‐9,</p> <p>Moderate 9‐12, Severe &gt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐class improvement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inactive:0‐2,</p> <p>Mild 3‐6,</p> <p>Moderate 7‐15,</p> <p>Severe &gt; 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response: &lt; 2 or 2‐3 class decrease</p> <p>Partial response: class improvement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inactive:0‐2,</p> <p>Mild 3‐6,</p> <p>Moderate 7‐15,</p> <p>Severe &gt; 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS &gt; 3 considered positive</p> <p>intestinal inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <p><b>Setting</b> </p> <p>Three studies were based on prospective assessment during an endoscopy procedure with two raters viewing at the same time (<a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a>; <a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>; <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>). Similarly, 16 studies were based on prospective assessment during an endoscopy procedure, but with a single rater (<a href="./references#CD010642-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. ">Colombel 2003</a>; <a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a>; <a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a>; <a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a>; <a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a>; <a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a>; <a href="./references#CD010642-bbs2-0019" title="RimolaJ , OrdasI , RodriguezS , Garcia‐BoschO , AceitunoM , LlachJ , et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflammatory Bowel Diseases2011;17(8):1759‐68. ">Rimola 2011</a>; <a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a>; <a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a>; <a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a>; <a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a>; <a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a>; <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>; <a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a>; <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>). Seven studies were based on retrospective review of endoscopy videos (<a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a>; <a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a>; <a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a>; <a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a>; <a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a>; <a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a>; <a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a>). For <a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a> and <a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a>, retrospective endoscopy rating was performed based on material in medical charts, however it was not clear how this was performed. <a href="./references#CD010642-bbs2-0018" title="ReinischW , RutgeertsPJ , PanaccioneR , D'HaensGR , ThakkarR , YuAP , et al. Prediction of long‐term clinical remission for adalimumab‐treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES‐CD. Gastroenterology2010;138(5 Suppl 1):S8. ">Reinisch 2010</a> and <a href="./references#CD010642-bbs2-0022" title="RutgeertsPJ , ReinischW , ThakkarR , WuEQ , KaltenboeckA , YangM , et al. Early mucosal healing status predicts long‐term clinical benefits for adalimumab‐treated patients with moderate to severe Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S85. RutgeertsPJ , ThakkarR , WuEQ , KaltenboeckA , YangM , MulaniP , et al. Quality‐of‐life benefits for adalimumab‐treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status. Gastroenterology2010;138(5 Suppl 1):S320. ">Rutgeerts 2010</a> did not specify how the assessments were performed. </p> <p><a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> described the development of the CDEIS in a multi‐phase study. During the development phase, colonoscopies from 75 patients were assessed by two endoscopists in the same room. Data on mucosal lesions, the percentage of segmental surfaces with disease involvement, and the percentage of segmental surfaces with ulcerations were evaluated in five endoscopic segments (rectum, sigmoid and left colon, transverse colon, right colon, and ileum). Multiple linear regression identified independent variables correlated with the Global Evaluation of Lesion Severity (GELS) to generate an overall score. In the next phase of the study, agreement was assessed based on the intra‐class correlation coefficient (ICC) and the correlation between the CDEIS with the GELS was used to determine criterion validity. In the final phase, 54 patients with active Crohn’s disease underwent colonoscopies at baseline and three to five weeks after oral prednisone (1mg/kg/day) to determine the responsiveness of the CDEIS. </p> <p>The SES‐CD was originally constructed in a four part study (<a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>). In part one, the reproducibility of the several items were examined. Two endoscopists scored 71 colonoscopies to assess ulcer size, the proportion of the surface with ulcers, the proportion of the mucosal surface affected with disease, and stenosis in five endoscopic segments (rectum, sigmoid and left colon, transverse colon, right colon, and ileum). Part two of the study developed the SES‐CD using multiple linear regressions of items with strong reproducibility. As a result of this process, the SES‐CD was defined as the sum of four variables over five colonic segments. The validation phase comprised part three of the study, in which 121 additional patients were included. The statistical correlation between the SES‐CD and the CDEIS was calculated. The fourth part of this study evaluated the reliability of the SES‐CD and CDEIS, including correlation with clinical parameters such as the CDAI, the Inflammatory Bowel Disease Questionnaire (IBDQ), and biochemical markers (CRP and albumin). </p> </section> <section id="CD010642-sec-0045"> <h4 class="title">Excluded studies</h4> <p>Seven studies (<a href="./references#CD010642-bbs2-0031" title="BondjemahV , MaryJY , JonesJ , SandbornW , SchoepferA , LouisE , et al. Fecal calprotectin and CRP as biomarkers of endoscopic activity in Crohn’s disease: a meta‐study. Journal of Crohn's and Colitis2012;6(1):S63. ">Bondjemah 2012</a>; <a href="./references#CD010642-bbs2-0032" title="Mantzaris , GJ , ChristidouA , SfakianakisM , RoussosA , KoilakouS , PetrakiK , et al. Azathioprine Is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid‐dependent Crohn's disease. Inflammatory Bowel Diseases2009;15(3):375‐82. ">Mantzaris 2009</a>; <a href="./references#CD010642-bbs2-0033" title="ModiglianiR , MaryJY . Reproducibility of colonoscopic findings in Crohn's disease: A prospective multicenter study of interobserver variation. Digestive Diseases and Sciences1987;32(12):1370‐9. ">Modigliani 1987</a>; <a href="./references#CD010642-bbs2-0034" title="SandbornW , ColombelJF , AllezM , DupasJL , DewitO , D'HaensG , et al. Certolizumab pegol plasma concentrations and endoscopic and clinical outcomes in Crohn's disease: a post hoc analysis of the MUSIC trial. American Journal of Gastroenterology2012;107 Suppl 1:S674‐5. ">Sandborn 2012a</a>; <a href="./references#CD010642-bbs2-0035" title="SandbornW , PanaccioneR , ColombelJF , LouisE , YangM , ThakkarR , et al. Development of three practical indices for mucosal healing among patients with moderate to severe Crohn’s disease. Journal of Crohn's and Colitis2012;6(1):S3. SandbornWJ , PanaccioneR , ColombelJF , LouisE , YangM , ThakkarR , et al. Development of three practical indices for mucosal healing among patients with moderate to severe Crohn's disease. Gastroenterology2012;142(5 Suppl 1):S537. SandbornWJ , PanaccioneR , ColombelJF , LouisE , YangM , ThakkarR , et al. Development of three practical indices for mucosal healing among patients with moderate to severe Crohn's disease. Inflammatory Bowel Diseases2012;18:S39‐40. ">Sandborn 2012b</a>; <a href="./references#CD010642-bbs2-0036" title="SandbornW , ColombelJF , LouisE , PanaccioneR , YangM , ChaoJ , et al. Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE. Journal of Crohn's and Colitis2012;6(1):S169‐70. SandbornW , ColombelJF , LouisE , PanaccioneR , YangM , ChaoJ , et al. Adalimumab sustains deep remission for 3 years: data from CHARM and ADHERE. Inflammatory Bowel Diseases2012;18:S38. ">Sandborn 2012c</a>; <a href="./references#CD010642-bbs2-0037" title="ZiechML , LaviniC , CaanMW , NioCY , StokkersPC , BipatS , et al. Dynamic contrast‐enhanced MRI in patients with luminal Crohn's disease. European Journal of Radiology2012;81(11):3019‐27. ">Ziech 2012</a>), were excluded with reasons (see <a href="./references#CD010642-sec-0068" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD010642-sec-0046"> <h3 class="title">Risk of bias in included studies</h3> <p>In <a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> multiple raters were in the same room during endoscopy to perform mucosal assessments. The authors state that independence of observation was upheld, but it is plausible that non‐verbal communication could influence scoring yielding high agreement (e.g. the endoscopist pausing at an ulcer or facial reactions could bias the observer). </p> <p>Similarly, multiple raters were in the same room in <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>. The authors state the endoscopist and the observer did not communicate during the colonoscopic examination, and they completed the endoscopic scoring sheets independently. </p> <p>In many studies a single rater assessed endoscopic disease activity (<a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a>; <a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a>; <a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a>; <a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a>; <a href="./references#CD010642-bbs2-0018" title="ReinischW , RutgeertsPJ , PanaccioneR , D'HaensGR , ThakkarR , YuAP , et al. Prediction of long‐term clinical remission for adalimumab‐treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES‐CD. Gastroenterology2010;138(5 Suppl 1):S8. ">Reinisch 2010</a>; <a href="./references#CD010642-bbs2-0019" title="RimolaJ , OrdasI , RodriguezS , Garcia‐BoschO , AceitunoM , LlachJ , et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflammatory Bowel Diseases2011;17(8):1759‐68. ">Rimola 2011</a>; <a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a>; <a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a>; <a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a>; <a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a>; <a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a>; <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>; <a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a>; <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>). As a result rater independence was not relevant, but differences in training and expertise could cause variation. Additionally, results for a single expert reviewer may not be generalizable to other assessors. Several studies did not describe the process for selection of readers or the number of readers who evaluated each endoscopy. It is possible that a single reader assessed the endoscopy, or that independence of observation was not considered in the trial design (<a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a>; <a href="./references#CD010642-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. ">Colombel 2003</a>; <a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a>; <a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a>; <a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a>; <a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a>; <a href="./references#CD010642-bbs2-0018" title="ReinischW , RutgeertsPJ , PanaccioneR , D'HaensGR , ThakkarR , YuAP , et al. Prediction of long‐term clinical remission for adalimumab‐treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES‐CD. Gastroenterology2010;138(5 Suppl 1):S8. ">Reinisch 2010</a>; <a href="./references#CD010642-bbs2-0022" title="RutgeertsPJ , ReinischW , ThakkarR , WuEQ , KaltenboeckA , YangM , et al. Early mucosal healing status predicts long‐term clinical benefits for adalimumab‐treated patients with moderate to severe Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S85. RutgeertsPJ , ThakkarR , WuEQ , KaltenboeckA , YangM , MulaniP , et al. Quality‐of‐life benefits for adalimumab‐treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status. Gastroenterology2010;138(5 Suppl 1):S320. ">Rutgeerts 2010</a>). </p> <p>In studies with multiple readers assessing each endoscopy that did not report inter‐rater reliability there is a potential concern that readers were not consistent (<a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a>). The process of reader training and testing, to ensure consistency of assessments between readers, was unclear in these circumstances. </p> <section id="CD010642-sec-0047"> <h4 class="title">Blinding</h4> <p>Blinding to clinical information such as symptoms, physical examination or laboratory information is important for the objective assessment of endoscopic data (<a href="./references#CD010642-bbs2-0043" title="FeaganBG , SandbornWJ , D'HaensG , PolaS , McDonaldJW , RutgeertsP , et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology2013;145(1):149‐57. ">Feagan 2013</a>). The presence or absence of blinding was not routinely reported. </p> <p>In 10 studies, raters were blinded to clinical information (<a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a>; <a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a>; <a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a>; <a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a>; <a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a>; <a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a>; <a href="./references#CD010642-bbs2-0019" title="RimolaJ , OrdasI , RodriguezS , Garcia‐BoschO , AceitunoM , LlachJ , et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflammatory Bowel Diseases2011;17(8):1759‐68. ">Rimola 2011</a>; <a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a>; <a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a>; <a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a>). In three studies, raters appeared to be partially blinded to clinical information (<a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a>; <a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a>; <a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a>). In 12 studies, it was not clear if assessors were blinded to clinical information (<a href="./references#CD010642-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. ">Colombel 2003</a>; <a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a>; <a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a>; <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>; <a href="./references#CD010642-bbs2-0018" title="ReinischW , RutgeertsPJ , PanaccioneR , D'HaensGR , ThakkarR , YuAP , et al. Prediction of long‐term clinical remission for adalimumab‐treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES‐CD. Gastroenterology2010;138(5 Suppl 1):S8. ">Reinisch 2010</a>; <a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a>; <a href="./references#CD010642-bbs2-0022" title="RutgeertsPJ , ReinischW , ThakkarR , WuEQ , KaltenboeckA , YangM , et al. Early mucosal healing status predicts long‐term clinical benefits for adalimumab‐treated patients with moderate to severe Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S85. RutgeertsPJ , ThakkarR , WuEQ , KaltenboeckA , YangM , MulaniP , et al. Quality‐of‐life benefits for adalimumab‐treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status. Gastroenterology2010;138(5 Suppl 1):S320. ">Rutgeerts 2010</a>; <a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a>; <a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a>; <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>; <a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a>; <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>). Finally, in five studies, it appeared that raters were not blinded to clinical information (<a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a>; <a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>; <a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a>; <a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a>). In studies where the assessment was performed by a local endoscopist, it is likely that the rater would have access to clinical data. </p> <p>Results from the COSMIN assessment of methodological quality are reported in the <a href="#CD010642-sec-0051">Effects of methods</a> section. </p> </section> <section id="CD010642-sec-0048"> <h4 class="title">Incomplete outcome data</h4> <p>Differences in validity comparisons observed for the both the SES‐CD and CDEIS (such as variation observed between correlation to CRP and fecal calprotectin) may be due to the heterogenous populations studied in terms of severity and history of CD as well as length of follow‐up. Thus, no meta‐analysis or summary measures of correlation were reported in this systematic review due to the differences in study designs. </p> <p>Reliability estimates may also be influenced by sample selection and exclusions. Studies that did not include the full spectrum of disease activity could have improved ICC estimates. For example, a sample with primarily extreme populations (complete remission or severe CD) are less subjective to score consistently. Therefore, this may be one reason for differences observed in inter‐rater agreement. </p> </section> <section id="CD010642-sec-0049"> <h4 class="title">Selective reporting</h4> <p>Our search included a review of the grey literature and hand‐searching of abstracts, but there is potential that unpublished validation data were not included in this review. However, there is limited risk that a major validation study was missed. </p> </section> <section id="CD010642-sec-0050"> <h4 class="title">Other potential sources of bias</h4> <p>No other potential sources of bias were identified.</p> </section> </section> <section id="CD010642-sec-0051"> <h3 class="title" id="CD010642-sec-0051">Effect of methods</h3> <p><b>Reliability</b> </p> <p>One study assessed intra‐rater reliability (agreement with self over multiple assessments of the same endoscopy video) for both the SES‐CD and CDEIS (<a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a>). The overall ICCs were 0.91 (95% CI 0.89 to 0.95) and 0.89 (95% CI 0.86 to 0.93) for the SES‐CD and CDEIS, respectively (see <a href="#CD010642-tbl-0003">Table 3</a>). </p> <div class="table" id="CD010642-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reliability</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inter‐rater kappa</b> </p> <p><b>(between raters)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inter‐rater ICC</b> </p> <p><b>(between raters)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intra‐rater</b> </p> <p><b>kappa</b> </p> <p><b>(within rater)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intra‐rater ICC</b> </p> <p><b>(within rater)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Internal Consistency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulcers:</p> <p>Ileum: 0.884,</p> <p>Right Colon: 0.919,</p> <p>Transverse Colon: 0.972,</p> <p>Left Colon: 0.857,</p> <p>Rectum: 0.819<br/> <br/> Ulcerated Surface: </p> <p>Ileum: 0.882,</p> <p>Right Colon: 0.811,</p> <p>Transverse Colon: 0.942,</p> <p>Left Colon: 0.878,</p> <p>Rectum: 0.857<br/> <br/> Affected Surface: </p> <p>Ileum: 0.811,</p> <p>Right Colon: 0.791,</p> <p>Transverse Colon: 0.841,</p> <p>Left Colon: 0.909,</p> <p>Rectum: 0.838<br/> <br/> Stenosis: </p> <p>Ileum: 1.000,</p> <p>Right Colon: 1.000,</p> <p>Transverse Colon: 1.000,</p> <p>Left Colon: 1.000,</p> <p>Rectum: NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICC: 0.9815 (95% CI 0.9705 to 0.9884)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Average measures:<br/> ICC 0.994 (95% CI 0.976‐1.000)<br/> <br/> Single measures:<br/> ICC 0.929 (95% CI 0.757‐0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (95% CI 0.75 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (95% CI 0.89 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline: 0.77 (95% CI 0.69 to 0.83)</p> <p>Week 12: 0.86 (95% CI 0.81 to 0.90)</p> <p>Week 52: 0.82 (95% CI 0.73 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deep Ulcers:</p> <p>Ileum: 0.683,</p> <p>Right Colon: 0.811,</p> <p>Transverse Colon: 1.000,</p> <p>Left Colon: 0.900,</p> <p>Rectum: 0.666<br/> <br/> Superficial Ulcers: </p> <p>Ileum: 0.701,</p> <p>Right Colon: 0.727, Transverse Colon: 0.738,</p> <p>Left Colon: 0.628,</p> <p>Rectum: 0.767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICC: 0.9090 (95% CI 0.8580 to 0.9423)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Average measures:<br/> ICC 0.985 (95% CI 0.939‐1.000) </p> <p>Single measures:<br/> ICC 0.835 (95% CI 0.540‐0.995) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 0 ICC: 0.60 (95%CI 0.39‐0.75)</p> <p>Week 10 ICC: 0.74 (95% CI 0.59‐0.84)</p> <p>Week 54 ICC: 0.81 (95% CI 0.65‐0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (95% CI 0.63 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (95% CI 0.86 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICC: 0.96 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline: 0.78 (95% CI 0.65 to 0.87)</p> <p>Week 12: 0.92 (95% CI 0.86 to 0.95)</p> <p>Week 52: 0.86 (95% CI 0.73 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>No studies assessed intra‐rater reliability</p> </div> </div> <p>For the SES‐CD, inter‐rater reliability (agreement between raters) was assessed in four studies (<a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>; <a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a>; <a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a>; <a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a>; see <a href="#CD010642-tbl-0003">Table 3</a>). <a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> was the original validation paper for the SES‐CD, and provided inter‐rater reliability data using observer pairs. Both the ICC for the total score and kappa values for components of the SES‐CD score were reported (<a href="#CD010642-tbl-0003">Table 3</a>). The overall ICC is 0.9815, 95% CI 0.9705 to 0.9884 and the kappa for the regions is high, however the paired raters were located in the same room. The publication states there was no communication among endoscopists and that scoring sheets were completed independently, however there exists a potential for bias as described in the <a href="#CD010642-sec-0038">Assessment of risk of bias in included studies</a> section. <a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a> examined eight endoscopic videos with 13 raters, and also found high ICC (&gt; 0.9) (<a href="#CD010642-tbl-0003">Table 3</a>). <a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a> observed overall ICCs of 0.77 (95% CI 0.69 to 0.83) at baseline, 0.86 (0.81 to 0.90) at week 12, and 0.82 (95% CI 0.73 to 0.88) at week 52. </p> <p>For the CDEIS, inter‐rater reliability was assessed in six studies (<a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>; <a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a>; <a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a>; <a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a>; <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>; <a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a> see <a href="#CD010642-tbl-0003">Table 3</a>). <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> was the original validation paper for the CDEIS and provided inter‐rater reliability data using observer pairs, where the observer viewed through a teaching tube. <a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> compared the SES‐CD to the CDEIS and found the ICC for the CDEIS was 0.9090 (95% CI 0.8580‐0.9423) and also reported kappa values for components of the CDEIS score, which tended to be lower than those reported for the SES‐CD. <a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a> reported for the CDEIS the ICC was 0.985 (95% CI 0.939‐1.000) for average measures and was 0.835 (95% CI 0.540‐0.995) for single measures. In <a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a> blinded and independent reviews of endoscopic videos were assessed in duplicate. The ICCs were 0.60 (95% CI 0.39‐0.75) at baseline, 0.74 (95% CI 0.59‐0.84) at week 10, and 0.81 (95% CI 0.65‐0.90) at week 54. Rutgeerts 2016 reported the overall ICCs to be 0.78 (95% CI 0.65 to 0.7) at baseline, 0.92 (95% CI 0.86 to 0.95) at week 12, and 0.86 (95% CI 0.73 to 0.93) at week 52. </p> <p>Although higher numerical values were observed for the SES‐CD compared to the CDEIS, both indices demonstrated good inter‐rater reliability in these limited number of studies. </p> <p><b>Validity</b> </p> <p><i><b>Content validity</b> </i> </p> <p>No studies assessed the content validity of the SES‐CD or CDEIS (see <a href="#CD010642-tbl-0004">Table 4</a>) </p> <div class="table" id="CD010642-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Content Validity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*no studies assessed content validity</p> </div> </div> <p><i><b>Criterion validity</b> </i> </p> <p>For both the SES‐CD and CDEIS, correlation between endoscopic score and clinical measures, including CRP, ESR, fecal calprotectin, and fecal lactoferrin were reported (see <a href="#CD010642-tbl-0005">Table 5</a>). The correlations ranged from poor to excellent, with the highest correlations observed between CDEIS and fecal calprotectin (r = 0.831) and CDEIS and fecal lactoferrin (r = 0.865). </p> <div class="table" id="CD010642-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Criterion Validity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Correlation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.56 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.56 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.621 ( p = ?)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.399 (p = ?)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.472 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBDQ, serum albumin, BMI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"no correlation"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"no correlation"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP change: r = 0.47 (p = 0.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP change:</p> <p>r = 0.28 (p = 0.0002)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP change:</p> <p>r = 0.27 (p = 0.0004)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.68 (p = 0.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"did not correlate"</p> <p>(p = 0.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal SES‐CD to Ileal CTE:</p> <p>r = 0.69 (p = 0.007)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.46 p &lt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.45 (p &lt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lactoferrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.48 (&lt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*r = 0.650 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*r = 0.807 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*r = 0.397 (p = 0.015)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*r = 0.650 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*r = 0.807 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*r = 0.397 (p = 0.015)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = ?</p> <p>SES‐CD &lt; 2 and PGA = 0</p> <p>showed difference in CRP vs. active disease (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = ?</p> <p>SES‐CD &lt; 2 and PGA = 0</p> <p>showed difference in calprotectin vs. active disease (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0022" title="RutgeertsPJ , ReinischW , ThakkarR , WuEQ , KaltenboeckA , YangM , et al. Early mucosal healing status predicts long‐term clinical benefits for adalimumab‐treated patients with moderate to severe Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S85. RutgeertsPJ , ThakkarR , WuEQ , KaltenboeckA , YangM , MulaniP , et al. Quality‐of‐life benefits for adalimumab‐treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status. Gastroenterology2010;138(5 Suppl 1):S320. ">Rutgeerts 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI change: 1 point increase in CDAI at week 12 associated with 5 point increase in CDAI by week 52 (p &lt; 0.05) </p> <p>IBDQ change:1 point decrease in SES‐CD at week 12 associated with 2 point decrease in IBDQ at week 52 (p &lt; 0.05) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0019" title="RimolaJ , OrdasI , RodriguezS , Garcia‐BoschO , AceitunoM , LlachJ , et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflammatory Bowel Diseases2011;17(8):1759‐68. ">Rimola 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MaRIA score: r = 0.8 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.53 (p &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.75 (p &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukocytes: r = 0.42 (p &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.553 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.729 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lactoferrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.773 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileocolonic/colonic:</p> <p>r = 0.642 (p &lt; 0.001)</p> <p>Ileal/upper GI:</p> <p>r = 0.317 (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lactoferrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileocolonic/colonic:</p> <p>r = 0.627 (p &lt; 0.001)</p> <p>Ileal/upper GI:</p> <p>r = 0.180 (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.608 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.831 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lactoferrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.865 (0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = ?</p> <p>If SES‐CD response:median calprotectin decrease from 1282 mg/g (range 156‐2277 mg/g) to 73 mg/g (range 7‐222; p = 0.005) </p> <p>If SES‐CD non‐response: median calprotectin decrease from 1017 mg/g (range 53‐3928 mg/g) to 223 mg/g (range 35‐15330 mg/g; p = 0.594) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lactoferrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = ?</p> <p>If SES‐CD response:median lactoferrin decrease from 223 mg/g (range 2.8‐802 mg/g) to 0.6 mg/g (range 0.0‐420 mg/g; p = 0.005) </p> <p>If SES‐CD non‐response: median lactoferrin decrease from 22.5 mg/g (range 2.1‐629) to 13.0 mg/g (range 3.5‐1259; p = 0.515) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.525 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = ? (p &gt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI change: r = 0.282 (p = 0.118)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.521 (p &lt; 0.001)</p> <p>CRP change:</p> <p>r = ? (p &gt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI change: r = 0.240 (p = 0.185)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>? (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lactoferrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>? (p &lt; 0.001)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NS = Not significant</p> <p>*Loboton 2012 unclear if "endoscopic activity" refers to SES‐CD or CDEIS</p> </div> </div> <p><b>CRP </b> </p> <p>For the SES‐CD, the estimates of correlation with CRP ranged from r = 0.46 (<a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a>) to r = 0.68 (<a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a>). Six additional studies published correlations within this range (<a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a>; <a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a>; <a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>; <a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a>; <a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a>; <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>). The correlation between change in CRP and change in SES‐CD was reported as r = 0.28 by <a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a>, and was not statistically significant in <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>. </p> <p>For the CDEIS, the estimates of correlation with CRP were r = 0.521 (<a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>), r = 0.553 (<a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a>) and r = 0.608 (<a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>). One study reported that a correlation between CDEIS and CRP did not exist (<a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a>). The correlation between the change in CRP and change in CDEIS was reported as r = 0.27 by <a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a>, r = 0.46 by <a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> and was not statistically significant in <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>. </p> <p>In <a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a> the correlation between endoscopic activity and CRP was reported as r = 0.650, however it is unclear whether endoscopic activity was defined using the SES‐CD or CDEIS. </p> <p><b>ESR </b> </p> <p>For the SES‐CD, <a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a> reported that the estimate of correlation with ESR was r = 0.399. <a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a> also explored the correlation between SES‐CD and ESR and found that the two did not correlate (p = 0.6), but did not report the r value. </p> <p>No studies explicitly investigated the correlation between CDEIS and ESR. In <a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a> the correlation between endoscopic activity and ESR was reported as r = 0.397, however it is unclear whether endoscopic activity was defined using the SES‐CD or CDEIS. </p> <p><b>Fecal calprotectin </b> </p> <p>For the SES‐CD, the estimates of correlation with fecal calprotectin were r = 0.45 (<a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a>), r = 0.525 (<a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>), r = 0.56 (<a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a>), and r = 0.75 (<a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a>). <a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a> reported a correlation of r = 0.642 for patients with ileocolonic or colonic disease, and r = 0.317 for patients with disease affecting the ileum or upper gastrointestinal tract. No r values were reported in <a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a>, however patients with a SES‐CD defined response had a mean decrease in fecal calprotectin (from 1282 mg/g to 73 mg/g, p = 0.005). Patients without a response, as defined by SES‐CD, had a lower mean decrease in fecal calprotectin (from 1017 mg/g to 223 mg/g, p = 0.594). </p> <p>For the CDEIS, estimates of correlation with fecal calprotectin were reported as r = 0.729 in <a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a> and r = 0.831 in <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>. In <a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a> no correlation was detected, but the authors failed to report an r value. </p> <p>In <a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a> the correlation between endoscopic activity and fecal calprotectin was r = 0.807, however it is unclear whether endoscopic activity was defined using the SES‐CD or CDEIS. </p> <p><b>Fecal lactoferrin </b> </p> <p>For the SES‐CD, the estimates of correlation with fecal lactoferrin were r = 0.672 for patients with ileocolonic or colonic disease, and r = 0.180 for patients with disease affecting the ileum and or upper gastrointestinal tract (<a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a>). The later correlation was not statistically significant. No r value was reported in <a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a>, however patients with an SES‐CD defined response had a mean decrease in fecal calprotectin from 223 mg/g to 0.6 mg/g (p = 0.005). Patients without an SES‐CD defined response had a mean decrease in fecal calprotectin from 22.5 mg/g to 13.0 mg/g (p = 0.515). </p> <p>For the CDEIS, estimates of correlation with fecal lactoferrin were r = 0.773 in <a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a> and r = 0.865 in <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>. </p> <p><i><b>Construct validity</b> </i> </p> <p>With regard to construct validity, the correlations ranged from poor to excellent. The highest correlations observed between the SES‐CD and CDAI (r = 0.92), CDEIS and CDAI (r = 0.92), CDEIS and the Global Evaluation of Lesion Severity (GELS) (r = 0.83) and the CDEIS and SES‐CD (r = 0.968). </p> <p>For the SES‐CD, estimates of correlation with the CDAI ranged from r = 0.15 (<a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a>) to r = 0.92 (<a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a>). Five additional studies published correlations within this range (r = 0.4 <a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a>; r = 0.39 <a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>; r = 0.38 <a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a>; r = 0.346 <a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a>; and r = 0.473 <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>). In <a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a> the estimate of correlation between mean change in SES‐CD and CDEIS was r = 0.27. Two studies reported estimates of correlation between the SES‐CD and Harvey‐Bradshaw Index (HBI) as r = 0.32 (<a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a>) and r = 0.70 (<a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a>). In <a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a> the estimate of correlation between the SES‐CD and Modified Rutgeerts Score was r = 0.748. See <a href="#CD010642-tbl-0006">Table 6</a>. </p> <div class="table" id="CD010642-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Construct Validity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Correlation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Harvey</p> <p>Bradshaw</p> <p>Index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.32 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified Rutgeerts</p> <p>Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.748 (p value ?)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. ">Colombel 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"positively correlated"</p> <p>r = ? (p = 0.034)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.357 (p &lt; 0.001)<br/> <br/> CDEIS multiple regression correlation coefficient: </p> <p>0.920 (95% CI 0.8740, 0.9497)</p> <p>Spearman rank correlation coefficients:</p> <p>0.887 (95% CI 0.842, 0.920) and 0.910 (95% CI 0.873, 0.936)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"no correlation" to CDEIS</p> <p>&gt; 6 versus &lt;6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ΔCDAI to ΔCDEIS</p> <p>r = 0.56 (p = 0.002)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.810 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ΔCDAI to ΔSES‐CD</p> <p>r = 0.27 (p = 0.0003)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ΔCDEIS to ΔSES‐CD</p> <p>r = 0.89 (p &lt; 0.0001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ΔCDAI to ΔCDEIS</p> <p>r = 0.22 (p &lt; 0.0045)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HBI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.70 (p = 0.009)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.15 (p &gt; 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.92 (95% CI 0.88 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GELS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.74 (95% CI 0.64 to 0.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.92 (95% CI 0.88 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GELS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.75 (95% CI 0.67 to 0.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.968 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.442 (p = 0.004)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GELS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.83 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ΔCDAI to ΔCDEIS</p> <p>a) Week 10 r=0.307 (p=0.021)</p> <p>b)Week 54 r=0.498 (p&lt;0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ΔCDAI to ΔCDEIS</p> <p>a) Week 10 r=0.33 (p=0.002)</p> <p>b)Week 54 r=0.37 (p=0.003)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.38 (p &lt; 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.381 (p&lt;0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.346 (p&lt;0.001)</p> <p>(Spearmans rank order)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.592 (p = 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.473 (p &lt; 0.0001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.938 (p &lt; 0.0001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.446 (p &lt; 0.0001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <p>For the CDEIS, estimates of correlation with CDAI were reported as r = 0.92 in <a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a>, r = 0.442 in <a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a>, r = 0.381 in <a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a>, r = 0.592 in <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>, r = 0.446 in <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>. An estimate of correlation between mean change in CDEIS and CDAI was reported as r = 0.22 in <a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a>, r = 0.307 at week 10 and r = 0.498 at week 54 in <a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a>, and r = 0.33 at week 10, and r = 0.37 at week 54 in <a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a>. <a href="./references#CD010642-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. ">Colombel 2003</a> and Denis 2007 provided no r values, however the former found the CDEIS and CDAI to be positively correlated while the latter found no correlation between the two indices. <a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a> and <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> provided estimates of correlation between the CDEIS and the Global Evaluation of Lesion Severity (GELS) score of r = 0.74 and r = 0.83, respectively. <a href="#CD010642-tbl-0006">Table 6</a>. </p> <p>Five studies explored the relationship between the CDEIS and SES‐CD. Estimates of correlation were reported as r = 0.357 in <a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>, r = 0.810 in <a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a>, r = 0.968 in <a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a> and r = 0.938 in <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>. An estimate of correlation between mean change in CDEIS and SES‐CD was reported as r = 0.89 in <a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a>. See <a href="#CD010642-tbl-0006">Table 6</a>. </p> <p><b>Responsiveness</b> </p> <p>Minimal responsiveness data are available for the SES‐CD. <a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a> and <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> demonstrated statistically significant changes in the SES‐CD score after subjects were administered a treatment of known efficacy. <a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a> measured change after treatment, however statistics were only reported for a composite definition of corticosteroid‐free endoscopic response, not for individual EIs (see <a href="#CD010642-tbl-0007">Table 7</a>). </p> <div class="table" id="CD010642-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Responsiveness</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Responsiveness Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Association with Responsiveness Meaure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab</p> <p>a) 5 mg/kg</p> <p>b) 10 mg/kg</p> <p>c) 20 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS change after</p> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean decrease:</p> <p>a)15.1+/‐ 6.9 to 6.4+/‐5.1 (p &lt; 0.01)<br/> b)10.6+/‐ 7.8 to 4.3+/‐5.4 (p &lt; 0.01)<br/> c)13.3+/‐ 6.9 to 5.2+/‐2.8 (p &lt; 0.01)<br/> Overall: 13.0+/‐ 7.1 to 5.3+/‐4.4 (p &lt; 0.001) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine</p> <p>and/or Infliximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Note: Steroid free remission compared for</p> <p>endoscopic response definition but not</p> <p>specific to one EI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine</p> <p>and/or Infliximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Note: Steroid free remission compared for</p> <p>endoscopic response definition but not</p> <p>specific to one EI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Certolizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>a) CDEIS change</p> <p>b) Week 10</p> <p>c) Week 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>a) mean change: 3.79 (p &lt; 0.0001)</p> <p>b) mean change 5.7 (95% CI 4.6‐6.8)</p> <p>(p &lt; 0.0001)<br/> c) mean change 4.7 (95% CI 3.5 to 7.5) </p> <p>(p &lt; 0.0001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TNF‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS change</p> <p>a) Week 10 if Infliximab</p> <p>b) Week 12 if Adalimumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>a) mean CDEIS decrease 4.8 (p = ?)</p> <p>b) mean CDEIS decrease 5.068 (p = ?)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS change to change in</p> <p>GELS after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.72 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS change Week 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean change ‐4.9 with infliximab vs.‐2.0 in placebo group (p = 0.003)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% CDEIS change</p> <p>a) Week 10</p> <p>b) Week 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% change:<br/> a) 76% with 3 doses vs 32% with single dose (p &lt; 0.001)<br/> b) 93% in scheduled group vs. 54% in episodic group (p = 0.026) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TNF‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean decrease 8.2 (p = 0.002)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral therapy enhancement</p> <p>(budesonide, mesalamine,</p> <p>metronidazole or</p> <p>immunomodulator)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD at 4‐6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = ?</p> <p>SES‐CD decreased from 12 to 7</p> <p>(p = 0.006)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"CD therapy enhancement"</p> <p>13/32 received anti‐TNF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD decreased from 15 to 5</p> <p>(p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"CD therapy enhancement"</p> <p>13/32 received anti‐TNF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS decreased from 11.4 to 2.7</p> <p>(p &lt; 0.001)</p> </td> </tr> </tbody> </table> </div> <p>For the CDEIS, responsiveness data were available in nine studies (<a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a>; <a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a>; <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>; <a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a>; <a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a>; <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>; <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>). Seven studies demonstrated statistically significant decreases in the CDEIS score after administration of a treatment of known efficacy (<a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a>; <a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a>; <a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a>; <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>; <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>). Although <a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a> showed that the CDEIS decreased after treatment, significance testing was not performed. <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> demonstrated a correlation between changes in both the CDEIS and GELS scores after a treatment of known efficacy (see <a href="#CD010642-tbl-0007">Table 7</a>). These publications suggest that the CDEIS is a responsive measure of disease activity. </p> <p><b>Feasibility</b> </p> <p>No studies were identified that explicitly evaluated the feasibility of either the SES‐CD or the CDEIS. Both instruments require scoring by endoscopist. The SES‐CD is intuitively easier to use than the CDEIS, at it requires fewer calculations (see <a href="#CD010642-tbl-0008">Table 8</a>). </p> <div class="table" id="CD010642-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Feasibility</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Feasibility Scoring</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>No identified studies reported feasibiltiy scoring or item scaling</p> </div> </div> <p><b>Methodological Quality</b> </p> <p>The COSMIN tool was used to assess the methodological quality of the included studies. In total, 20 studies assessed criterion validity for the SES‐CD, CDEIS, or both indices. With regard to methodological quality, six of these studies were rated 'excellent' (<a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a>; <a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>; <a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a>; <a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a>; <a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a>; <a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a>), two were rated 'good' (<a href="./references#CD010642-bbs2-0022" title="RutgeertsPJ , ReinischW , ThakkarR , WuEQ , KaltenboeckA , YangM , et al. Early mucosal healing status predicts long‐term clinical benefits for adalimumab‐treated patients with moderate to severe Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S85. RutgeertsPJ , ThakkarR , WuEQ , KaltenboeckA , YangM , MulaniP , et al. Quality‐of‐life benefits for adalimumab‐treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status. Gastroenterology2010;138(5 Suppl 1):S320. ">Rutgeerts 2010</a>; <a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a>), five were rated 'fair' (<a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a>; <a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a>; <a href="./references#CD010642-bbs2-0019" title="RimolaJ , OrdasI , RodriguezS , Garcia‐BoschO , AceitunoM , LlachJ , et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflammatory Bowel Diseases2011;17(8):1759‐68. ">Rimola 2011</a>; <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>) and seven were rated 'poor' (<a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a>; <a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a>; <a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a>; <a href="./references#CD010642-bbs2-0018" title="ReinischW , RutgeertsPJ , PanaccioneR , D'HaensGR , ThakkarR , YuAP , et al. Prediction of long‐term clinical remission for adalimumab‐treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES‐CD. Gastroenterology2010;138(5 Suppl 1):S8. ">Reinisch 2010</a>; <a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a>; <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>; <a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a>). </p> <p>Nineteen studies assessed construct validity for the SES‐CD, CDEIS, or both indices. With regard to methodological quality, seven of these studies were rated 'excellent' (<a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a>; <a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>; <a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a>; <a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a>; <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>; <a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a>; <a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a>), three were rated 'good' (<a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a>; <a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a>; <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>), four were rated 'fair' (<a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a>; <a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a>; <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>), and four were rated 'poor' (<a href="./references#CD010642-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. ">Colombel 2003</a>; <a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a>; <a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a>; <a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a>. </p> <p>Five studies assessed reliability for the SES‐CD, CDEIS, or both indices. WIth regard to methodological quality, two of these studies were rated 'excellent' (<a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a>; <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>) and three were rated 'good' (<a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>; <a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a>; <a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a>). </p> <p>Eleven studies assessed responsiveness for the SES‐CD, CDEIS, or both indices. WIth regard to methodological quality, three of these studies were rated 'excellent' (<a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>; <a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a>; <a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a>), three were rated 'good' (<a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a>; <a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a>; <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>), four were rated 'fair' (<a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a>; <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>; <a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a>) and one was rated 'poor' (<a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a>). </p> <p>None of the included studies assessed content validity or feasibility for either the SES‐CD or CDEIS (See <a href="#CD010642-tbl-0009">Table 9</a> and <a href="#CD010642-tbl-0010">Table 10</a>). </p> <div class="table" id="CD010642-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Summary of Operating Properties of Endoscopic Scoring Indices for Crohn's Disease</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scoring index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Reliability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Responsiveness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Feasibility</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Content validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criterion validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Construct validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intra‐rater</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inter‐rater</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Test‐retest</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Internal consistency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CDEIS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SES‐CD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>+ positive rating</p> <p>? no information or indeterminate rating</p> <p>‐ Negative rating</p> </div> </div> <div class="table" id="CD010642-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">The Methodological Quality of Endoscopic Index Measurement Properties as Described in the Original Development Articles (COSMIN Checklist)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scoring index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Internal</b> </p> <p><b>consistency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reliability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measurement</b> </p> <p><b>error</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Content</b> </p> <p><b>validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Structural validity (CSV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypothesis</b> </p> <p><b>testing (CSV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross</b> </p> <p><b>‐cultural</b> </p> <p><b>validity (CSV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criterion</b> </p> <p><b>validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Responsiveness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interpretability</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. ">Colombel 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0018" title="ReinischW , RutgeertsPJ , PanaccioneR , D'HaensGR , ThakkarR , YuAP , et al. Prediction of long‐term clinical remission for adalimumab‐treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES‐CD. Gastroenterology2010;138(5 Suppl 1):S8. ">Reinisch 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0019" title="RimolaJ , OrdasI , RodriguezS , Garcia‐BoschO , AceitunoM , LlachJ , et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflammatory Bowel Diseases2011;17(8):1759‐68. ">Rimola 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0022" title="RutgeertsPJ , ReinischW , ThakkarR , WuEQ , KaltenboeckA , YangM , et al. Early mucosal healing status predicts long‐term clinical benefits for adalimumab‐treated patients with moderate to severe Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S85. RutgeertsPJ , ThakkarR , WuEQ , KaltenboeckA , YangM , MulaniP , et al. Quality‐of‐life benefits for adalimumab‐treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status. Gastroenterology2010;138(5 Suppl 1):S320. ">Rutgeerts 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CSV = construct validity</p> <p>? no information or indeterminate rating</p> </div> </div> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010642-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010642-sec-0052"></div> <section id="CD010642-sec-0053"> <h3 class="title" id="CD010642-sec-0053">Summary of main results</h3> <p>Forty‐five reports of 31 studies fulfilled the inclusion criteria; 43 reports of 30 studies were completed and reported results. </p> <p>For the SES‐CD, inter‐rater reliability was assessed in four studies (<a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>; <a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a>; <a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a>; <a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a>; see <a href="#CD010642-tbl-0003">Table 3</a>). In the development study for the SES‐CD (<a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>), the overall ICC is 0.9815, 95% CI 0.9705 to 0.9884 and kappa for the regions is high, however the paired raters were in the same room which introduces the potential for bias. </p> <p>For the CDEIS, inter‐rater reliability was assessed in six studies (<a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a>; <a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a>; <a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a>; <a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a>; <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>; <a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a> see <a href="#CD010642-tbl-0003">Table 3</a>). <a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a> reported the ICC for the CDEIS was 0.985 (95% CI 0.939‐1.000) for average measures of video score and was 0.835 (95% CI 0.540‐0.995) for single measures of video score. </p> <p>With respect to validity, correlation between the CDEIS and clinical measures, including CRP, ESR, fecal calprotectin and fecal lactoferrin was also reported (see <a href="#CD010642-tbl-0006">Table 6</a>). The estimates of correlation with CRP were r = 0.521 (<a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>), r = 0.553 (<a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a>) and r = 0.608 (<a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>). Correlation between the CDEIS and CRP, ESR, fecal calprotectin and fecal lactoferrin were also explored.The corresponding values for correlation with CRP ranged from r = 0.46 (<a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a>) to r=0.68 (<a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a>). </p> <p>For the CDEIS, responsiveness data were available in nine studies (<a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a>; <a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a>; <a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a>; <a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a>; <a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a>; <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>; <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>). Seven studies demonstrated statistically significant decreases in the CDEIS score after administration of a treatment of known efficacy (<a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a>; <a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a>; <a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a>; <a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a>; <a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a>; <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a>). Minimal responsiveness data are available for the SES‐CD. <a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a> and <a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> demonstrated statistically significant changes in the SES‐CD score after subjects were administered a treatment of known efficacy. </p> <p>No studies were identified that explicitly evaluated the feasibility for either the SES‐CD or the CDEIS. The SES‐CD requires fewer calculations and therefore may be easier to use than the CDEIS. </p> </section> <section id="CD010642-sec-0054"> <h3 class="title" id="CD010642-sec-0054">Overall completeness and applicability of evidence</h3> <p>Although several studies have evaluated various operating properties of the SES‐CD and CDEIS, many have solely focused on one or two operating properties, and contain methodological flaws. Further study is required to fully define the operating properties of these indices. </p> </section> <section id="CD010642-sec-0055"> <h3 class="title" id="CD010642-sec-0055">Quality of the evidence</h3> <p>The quality of evidence ranges from poor to excellent, and neither the SES‐CD nor CDEIS has been fully validated. </p> </section> <section id="CD010642-sec-0056"> <h3 class="title" id="CD010642-sec-0056">Potential biases in the review process</h3> <p>It should be noted that this review focused on the most commonly used endoscopic indices in Crohn's disease, the CDEIS and SES‐CD. However, there may be other endoscopic indices in Crohn's disease that have been subject to validation not represented in the current review. </p> </section> <section id="CD010642-sec-0057"> <h3 class="title" id="CD010642-sec-0057">Agreements and disagreements with other studies or reviews</h3> <p>We are unaware of other reviews on this topic.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010642-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/media/CDSR/CD010642/urn:x-wiley:14651858:media:CD010642:CD010642-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/media/CDSR/CD010642/image_t/tCD010642-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010642-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010642.pub2/media/CDSR/CD010642/image_n/nCD010642-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/media/CDSR/CD010642/image_n/nCD010642-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD010642-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of Included Studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of Readers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of CD</b> </p> <p><b>Patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of Endoscopies</b> </p> <p><b>and Reviews</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Material</b> </p> <p><b>Reviewed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Independent</b> </p> <p><b>Review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinded</b> </p> <p><b>Review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Operating Properties Assessed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210 colonoscopies</p> <p>Each SES‐CD scored by at least 2 gastroenterologists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supervised colonoscopies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> <p>Fecal calprotectin blinded</p> <p>but not other lab or</p> <p>clinical data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balloon enteroscopy,</p> <p>from medical charts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. ">Colombel 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (AZA or placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (Placebo: 8,<br/> IFX: 22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (30 pre, 30 post)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy (also recorded)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>a) Development of SES‐CD: 70 patients</p> <p>(endoscopist paired with observer</p> <p>for 35 of 70)<br/> b) Validation of SES‐CD: </p> <p>121 patients</p> <p>(endoscopist paired with second observer for 36 of 121)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy and live video feed:<br/> local endoscopist (70 +121), </p> <p>second observer from a television</p> <p>monitor (35 + 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliability; criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Videos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliability</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 videos (24 pre, 24 post)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Videos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172 (120 with high</p> <p>baseline CRP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>344 (172 pre, 172 post)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Videos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (15 with high HBI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chart review of colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 central readers,</p> <p>1 local</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 (44 with paired</p> <p>endoscopy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88 (44 pre, 44 post)</p> <p>2 central reviews per endoscopy</p> <p>133 videos with consent (49 at baseline, 51 at week 10, 33 at week 54)</p> <p>Each video was read by a pair of central readers (266 reads)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Videos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliability; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 patients (10 infliximab,</p> <p>10 adalimumab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 scopes (20 pre, 20 post)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>157 with SES‐CD scored</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 central readers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 central readers performed 3 independent measurements for each of the 50 videos</p> <p>Each of the 50 videos was replicated twice to create 150 samples that were read by the four readers in random order </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Videos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliability; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 patients (SES‐CD)</p> <p>46 patients (CDEIS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 colonoscopies performed; 89 were complete ileocolonoscopies</p> <p>46 colonoscopies performed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>a) 75</p> <p>b) 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>a) Reproducibility=75 patients (75 colonoscopies read twice = 150 reviews)</p> <p>b) Responsiveness=54 patients (103 colonoscopies read once)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy‐ one reader performing the</p> <p>procedure,</p> <p>one viewing through teaching tube</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliability; construct validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 8 (local)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183 (109 Infliximab,</p> <p>74 adalimumab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0018" title="ReinischW , RutgeertsPJ , PanaccioneR , D'HaensGR , ThakkarR , YuAP , et al. Prediction of long‐term clinical remission for adalimumab‐treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES‐CD. Gastroenterology2010;138(5 Suppl 1):S8. ">Reinisch 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186 with Baseline, week 12 and week 24 results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0019" title="RimolaJ , OrdasI , RodriguezS , Garcia‐BoschO , AceitunoM , LlachJ , et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflammatory Bowel Diseases2011;17(8):1759‐68. ">Rimola 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (single review but both reviewers involved: one performed examination</p> <p>and other annotated findings)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 patients (24 placebo,</p> <p>19 infliximab 5mg/kg, 23 infliximab 10 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>198 (baseline, Wk 10, Wk 54 for</p> <p>66 patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Construct validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99 (75 evaluated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231 (99 baseline, 74 week 10,</p> <p>58 week 54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy ‐ by local endoscopist,</p> <p>video ‐ by single reader for</p> <p>mucosal healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0022" title="RutgeertsPJ , ReinischW , ThakkarR , WuEQ , KaltenboeckA , YangM , et al. Early mucosal healing status predicts long‐term clinical benefits for adalimumab‐treated patients with moderate to severe Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S85. RutgeertsPJ , ThakkarR , WuEQ , KaltenboeckA , YangM , MulaniP , et al. Quality‐of‐life benefits for adalimumab‐treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status. Gastroenterology2010;138(5 Suppl 1):S320. ">Rutgeerts 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180 (baseline, week 12 and week 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity;</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 blinded central reader</p> <p>up to 2 designated endoscopists per site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline: 129</p> <p>Week 12: 122</p> <p>Week 52: 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline: 129</p> <p>Week 12: 122</p> <p>Week 52: 84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy and videos</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reliability;</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122 (plus 43 healthy controls)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140 colonoscopies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106 procedures (25 patients</p> <p>with 2 scopes, 2 patients with 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87 ileocolonoscopy in 61 patients</p> <p>(37 scoped once, 22 twice, 2 three times)</p> <p>Single read of each</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>? (blind to fecal assay results but unclear if they were aware of CDAI score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (14 infliximab,</p> <p>1 adalimumab)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 colonoscopies (baseline and week 12, or week 10 for</p> <p>adalimumab patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (19 at baseline and 19 at 4‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86,</p> <p>32 with second endoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 baseline, 32 follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity; construct validity; responsiveness</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 double balloon enteroscopies</p> <p>2 endoscopists reviewed each by video</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Video</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A ‐ single review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Criterion validity</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of Included Studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010642-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Scoring Index Cut‐offs</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cut‐off</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outocme</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cut‐off</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission 0‐2;</p> <p>Mild 3‐6;</p> <p>Moderate 7‐15;</p> <p>Severe &gt; 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Musocal healing 0‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease of at least 50%</p> <p>and at least 5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease of at least 50%</p> <p>and at least 5 points</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease of at least 50%</p> <p>and at least 5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease of at least 50%</p> <p>and at least 5 points</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission: &lt; 6</p> <p>Complete Remission: &lt; 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS decrease of &gt; 5 points</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cutoff &gt; 7, predicted by</p> <p>biomarkers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission 0‐2;</p> <p>Mild 3‐6;</p> <p>Moderate 7‐15;</p> <p>Severe &gt; 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0018" title="ReinischW , RutgeertsPJ , PanaccioneR , D'HaensGR , ThakkarR , YuAP , et al. Prediction of long‐term clinical remission for adalimumab‐treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES‐CD. Gastroenterology2010;138(5 Suppl 1):S8. ">Reinisch 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cutoff &gt; 5 for</p> <p>predicting future remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inactive:0‐3,</p> <p>Mild 4‐10,</p> <p>Moderate 11‐19,</p> <p>High &gt;=20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inactive:0‐2,</p> <p>Mild 3‐9,</p> <p>Moderate 9‐12, Severe &gt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suggested cutoff 3 for inactive,</p> <p>but still unsettled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inactive:0‐2,</p> <p>Mild 3‐9,</p> <p>Moderate 9‐12, Severe &gt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐class improvement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inactive:0‐2,</p> <p>Mild 3‐6,</p> <p>Moderate 7‐15,</p> <p>Severe &gt; 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Response: &lt; 2 or 2‐3 class decrease</p> <p>Partial response: class improvement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inactive:0‐2,</p> <p>Mild 3‐6,</p> <p>Moderate 7‐15,</p> <p>Severe &gt; 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS &gt; 3 considered positive</p> <p>intestinal inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Scoring Index Cut‐offs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010642-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reliability</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inter‐rater kappa</b> </p> <p><b>(between raters)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inter‐rater ICC</b> </p> <p><b>(between raters)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intra‐rater</b> </p> <p><b>kappa</b> </p> <p><b>(within rater)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intra‐rater ICC</b> </p> <p><b>(within rater)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Internal Consistency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulcers:</p> <p>Ileum: 0.884,</p> <p>Right Colon: 0.919,</p> <p>Transverse Colon: 0.972,</p> <p>Left Colon: 0.857,</p> <p>Rectum: 0.819<br/> <br/> Ulcerated Surface: </p> <p>Ileum: 0.882,</p> <p>Right Colon: 0.811,</p> <p>Transverse Colon: 0.942,</p> <p>Left Colon: 0.878,</p> <p>Rectum: 0.857<br/> <br/> Affected Surface: </p> <p>Ileum: 0.811,</p> <p>Right Colon: 0.791,</p> <p>Transverse Colon: 0.841,</p> <p>Left Colon: 0.909,</p> <p>Rectum: 0.838<br/> <br/> Stenosis: </p> <p>Ileum: 1.000,</p> <p>Right Colon: 1.000,</p> <p>Transverse Colon: 1.000,</p> <p>Left Colon: 1.000,</p> <p>Rectum: NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICC: 0.9815 (95% CI 0.9705 to 0.9884)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Average measures:<br/> ICC 0.994 (95% CI 0.976‐1.000)<br/> <br/> Single measures:<br/> ICC 0.929 (95% CI 0.757‐0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (95% CI 0.75 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (95% CI 0.89 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline: 0.77 (95% CI 0.69 to 0.83)</p> <p>Week 12: 0.86 (95% CI 0.81 to 0.90)</p> <p>Week 52: 0.82 (95% CI 0.73 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deep Ulcers:</p> <p>Ileum: 0.683,</p> <p>Right Colon: 0.811,</p> <p>Transverse Colon: 1.000,</p> <p>Left Colon: 0.900,</p> <p>Rectum: 0.666<br/> <br/> Superficial Ulcers: </p> <p>Ileum: 0.701,</p> <p>Right Colon: 0.727, Transverse Colon: 0.738,</p> <p>Left Colon: 0.628,</p> <p>Rectum: 0.767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICC: 0.9090 (95% CI 0.8580 to 0.9423)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Average measures:<br/> ICC 0.985 (95% CI 0.939‐1.000) </p> <p>Single measures:<br/> ICC 0.835 (95% CI 0.540‐0.995) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Week 0 ICC: 0.60 (95%CI 0.39‐0.75)</p> <p>Week 10 ICC: 0.74 (95% CI 0.59‐0.84)</p> <p>Week 54 ICC: 0.81 (95% CI 0.65‐0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (95% CI 0.63 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (95% CI 0.86 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICC: 0.96 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline: 0.78 (95% CI 0.65 to 0.87)</p> <p>Week 12: 0.92 (95% CI 0.86 to 0.95)</p> <p>Week 52: 0.86 (95% CI 0.73 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>No studies assessed intra‐rater reliability</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reliability</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010642-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Content Validity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>*no studies assessed content validity</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Content Validity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010642-tbl-0005"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Criterion Validity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Correlation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.56 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.56 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.621 ( p = ?)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.399 (p = ?)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.472 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IBDQ, serum albumin, BMI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"no correlation"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"no correlation"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP change: r = 0.47 (p = 0.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP change:</p> <p>r = 0.28 (p = 0.0002)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP change:</p> <p>r = 0.27 (p = 0.0004)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.68 (p = 0.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"did not correlate"</p> <p>(p = 0.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileal SES‐CD to Ileal CTE:</p> <p>r = 0.69 (p = 0.007)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.46 p &lt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.45 (p &lt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lactoferrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.48 (&lt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*r = 0.650 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*r = 0.807 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*r = 0.397 (p = 0.015)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*r = 0.650 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*r = 0.807 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ESR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*r = 0.397 (p = 0.015)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = ?</p> <p>SES‐CD &lt; 2 and PGA = 0</p> <p>showed difference in CRP vs. active disease (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = ?</p> <p>SES‐CD &lt; 2 and PGA = 0</p> <p>showed difference in calprotectin vs. active disease (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0022" title="RutgeertsPJ , ReinischW , ThakkarR , WuEQ , KaltenboeckA , YangM , et al. Early mucosal healing status predicts long‐term clinical benefits for adalimumab‐treated patients with moderate to severe Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S85. RutgeertsPJ , ThakkarR , WuEQ , KaltenboeckA , YangM , MulaniP , et al. Quality‐of‐life benefits for adalimumab‐treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status. Gastroenterology2010;138(5 Suppl 1):S320. ">Rutgeerts 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI change: 1 point increase in CDAI at week 12 associated with 5 point increase in CDAI by week 52 (p &lt; 0.05) </p> <p>IBDQ change:1 point decrease in SES‐CD at week 12 associated with 2 point decrease in IBDQ at week 52 (p &lt; 0.05) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0019" title="RimolaJ , OrdasI , RodriguezS , Garcia‐BoschO , AceitunoM , LlachJ , et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflammatory Bowel Diseases2011;17(8):1759‐68. ">Rimola 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MaRIA score: r = 0.8 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.53 (p &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.75 (p &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukocytes: r = 0.42 (p &lt; 0.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.553 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.729 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lactoferrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.773 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileocolonic/colonic:</p> <p>r = 0.642 (p &lt; 0.001)</p> <p>Ileal/upper GI:</p> <p>r = 0.317 (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lactoferrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ileocolonic/colonic:</p> <p>r = 0.627 (p &lt; 0.001)</p> <p>Ileal/upper GI:</p> <p>r = 0.180 (NS)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.608 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.831 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lactoferrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.865 (0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = ?</p> <p>If SES‐CD response:median calprotectin decrease from 1282 mg/g (range 156‐2277 mg/g) to 73 mg/g (range 7‐222; p = 0.005) </p> <p>If SES‐CD non‐response: median calprotectin decrease from 1017 mg/g (range 53‐3928 mg/g) to 223 mg/g (range 35‐15330 mg/g; p = 0.594) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lactoferrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = ?</p> <p>If SES‐CD response:median lactoferrin decrease from 223 mg/g (range 2.8‐802 mg/g) to 0.6 mg/g (range 0.0‐420 mg/g; p = 0.005) </p> <p>If SES‐CD non‐response: median lactoferrin decrease from 22.5 mg/g (range 2.1‐629) to 13.0 mg/g (range 3.5‐1259; p = 0.515) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.525 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = ? (p &gt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI change: r = 0.282 (p = 0.118)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CRP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.521 (p &lt; 0.001)</p> <p>CRP change:</p> <p>r = ? (p &gt; 0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI change: r = 0.240 (p = 0.185)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calprotectin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>? (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lactoferrin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>? (p &lt; 0.001)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>NS = Not significant</p> <p>*Loboton 2012 unclear if "endoscopic activity" refers to SES‐CD or CDEIS</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Criterion Validity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010642-tbl-0006"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Construct Validity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Correlation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Harvey</p> <p>Bradshaw</p> <p>Index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.32 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Modified Rutgeerts</p> <p>Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.748 (p value ?)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. ">Colombel 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"positively correlated"</p> <p>r = ? (p = 0.034)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.357 (p &lt; 0.001)<br/> <br/> CDEIS multiple regression correlation coefficient: </p> <p>0.920 (95% CI 0.8740, 0.9497)</p> <p>Spearman rank correlation coefficients:</p> <p>0.887 (95% CI 0.842, 0.920) and 0.910 (95% CI 0.873, 0.936)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"no correlation" to CDEIS</p> <p>&gt; 6 versus &lt;6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ΔCDAI to ΔCDEIS</p> <p>r = 0.56 (p = 0.002)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.810 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ΔCDAI to ΔSES‐CD</p> <p>r = 0.27 (p = 0.0003)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ΔCDEIS to ΔSES‐CD</p> <p>r = 0.89 (p &lt; 0.0001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ΔCDAI to ΔCDEIS</p> <p>r = 0.22 (p &lt; 0.0045)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HBI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.70 (p = 0.009)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.15 (p &gt; 0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.92 (95% CI 0.88 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GELS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.74 (95% CI 0.64 to 0.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.92 (95% CI 0.88 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GELS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.75 (95% CI 0.67 to 0.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.968 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.442 (p = 0.004)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GELS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.83 (p &lt; 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ΔCDAI to ΔCDEIS</p> <p>a) Week 10 r=0.307 (p=0.021)</p> <p>b)Week 54 r=0.498 (p&lt;0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ΔCDAI to ΔCDEIS</p> <p>a) Week 10 r=0.33 (p=0.002)</p> <p>b)Week 54 r=0.37 (p=0.003)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.38 (p &lt; 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.381 (p&lt;0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.346 (p&lt;0.001)</p> <p>(Spearmans rank order)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.592 (p = 0.001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.473 (p &lt; 0.0001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.938 (p &lt; 0.0001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.446 (p &lt; 0.0001)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Construct Validity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010642-tbl-0007"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Responsiveness</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Responsiveness Measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Association with Responsiveness Meaure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab</p> <p>a) 5 mg/kg</p> <p>b) 10 mg/kg</p> <p>c) 20 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS change after</p> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean decrease:</p> <p>a)15.1+/‐ 6.9 to 6.4+/‐5.1 (p &lt; 0.01)<br/> b)10.6+/‐ 7.8 to 4.3+/‐5.4 (p &lt; 0.01)<br/> c)13.3+/‐ 6.9 to 5.2+/‐2.8 (p &lt; 0.01)<br/> Overall: 13.0+/‐ 7.1 to 5.3+/‐4.4 (p &lt; 0.001) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine</p> <p>and/or Infliximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Note: Steroid free remission compared for</p> <p>endoscopic response definition but not</p> <p>specific to one EI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine</p> <p>and/or Infliximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Note: Steroid free remission compared for</p> <p>endoscopic response definition but not</p> <p>specific to one EI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Certolizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>a) CDEIS change</p> <p>b) Week 10</p> <p>c) Week 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>a) mean change: 3.79 (p &lt; 0.0001)</p> <p>b) mean change 5.7 (95% CI 4.6‐6.8)</p> <p>(p &lt; 0.0001)<br/> c) mean change 4.7 (95% CI 3.5 to 7.5) </p> <p>(p &lt; 0.0001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TNF‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS change</p> <p>a) Week 10 if Infliximab</p> <p>b) Week 12 if Adalimumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>a) mean CDEIS decrease 4.8 (p = ?)</p> <p>b) mean CDEIS decrease 5.068 (p = ?)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS change to change in</p> <p>GELS after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = 0.72 (p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS change Week 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean change ‐4.9 with infliximab vs.‐2.0 in placebo group (p = 0.003)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% CDEIS change</p> <p>a) Week 10</p> <p>b) Week 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% change:<br/> a) 76% with 3 doses vs 32% with single dose (p &lt; 0.001)<br/> b) 93% in scheduled group vs. 54% in episodic group (p = 0.026) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TNF‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean decrease 8.2 (p = 0.002)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral therapy enhancement</p> <p>(budesonide, mesalamine,</p> <p>metronidazole or</p> <p>immunomodulator)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD at 4‐6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>r = ?</p> <p>SES‐CD decreased from 12 to 7</p> <p>(p = 0.006)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"CD therapy enhancement"</p> <p>13/32 received anti‐TNF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD decreased from 15 to 5</p> <p>(p &lt; 0.001)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"CD therapy enhancement"</p> <p>13/32 received anti‐TNF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS decreased from 11.4 to 2.7</p> <p>(p &lt; 0.001)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Responsiveness</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010642-tbl-0008"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Feasibility</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Feasibility Scoring</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>No identified studies reported feasibiltiy scoring or item scaling</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Feasibility</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010642-tbl-0009"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Summary of Operating Properties of Endoscopic Scoring Indices for Crohn's Disease</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scoring index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Reliability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Responsiveness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Feasibility</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Content validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criterion validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Construct validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intra‐rater</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inter‐rater</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Test‐retest</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Internal consistency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CDEIS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SES‐CD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>+ positive rating</p> <p>? no information or indeterminate rating</p> <p>‐ Negative rating</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Summary of Operating Properties of Endoscopic Scoring Indices for Crohn's Disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010642-tbl-0010"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">The Methodological Quality of Endoscopic Index Measurement Properties as Described in the Original Development Articles (COSMIN Checklist)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scoring index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Internal</b> </p> <p><b>consistency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reliability</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measurement</b> </p> <p><b>error</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Content</b> </p> <p><b>validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Structural validity (CSV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypothesis</b> </p> <p><b>testing (CSV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cross</b> </p> <p><b>‐cultural</b> </p> <p><b>validity (CSV)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criterion</b> </p> <p><b>validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Responsiveness</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interpretability</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0001" title="Af BjorkestenCG , NieminenU , ArkkilaP , TurunenU , SipponenT , FarkkilaM . Endoscopy at three months from start of anti‐TNF as a predictor for long‐term endoscopic remission in Crohn's disease. Journal of Crohn's and Colitis2012;6:S162. Af BjorkestenCG , NieminenU , TurunenU , ArkkilaP , SipponenT , FarkkilaM . Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti‐TNF‐treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology2012;47(5):528‐37. ">Af Borjorkesten 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0002" title="BambaS , AndohA , BanH , ImaedaH , MochizukiY , InatomiO . Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease. Journal of Gastroenterology and Hepatology2012;27:398. ">Bamba 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0003" title="ColombelJF , LemannM , BouhnikY , DuclosB , SouleJC , LereboursE , et al. Endoscopic healing of Crohn's ileo‐colitis with azathioprine. Gastroenterology2003;124(4 Suppl 1):A196‐7. ">Colombel 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0005" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60(4):505‐12. ">Daperno 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0006" title="DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG‐IBD study. Journal of Crohn's and Colitis2012;6:S125. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG‐IBD study. Gastroenterology 20102;142(5 Suppl 1):S536. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiA , CassinottiA , et al. Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG‐IBD study. Digestive and Liver Disease2012;44:S80‐1. DapernoM , ComberlatoM , BossaF , BianconeL , BonanomiAG , CassinottiA , et al. Inter‐observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Digestive and Liver Disease2014;46(11):969‐73. DapernoM , ComberlatoM , BossaF , BonanomiA , LombardiG , BianconeL , et al. Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program. Digestive and Liver Disease2014;46:S4. DapernoM , ComberlatoM , BossaF , BonanomiAG , LombardiG , BianconeL , et al. Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program. Gastroenterology2014;146(5 Suppl 1):S‐234. ">Daperno 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0007" title="DenisMA , ReenaersC , FontaineF , BelaicheJ , LouisE . Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level. Inflammatory Bowel Diseases2007;13(9):1100‐5. ">Denis 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0004" title="D'HaensG , VanDeventerS , VanHogezandR , ChalmersD , KotheC , BaertF , et al. Endoscopic and histological healing with infliximab anti‐tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology1999;116(5):1029‐34. ">D'Haens 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0008" title="FerranteM , NomanM , VermeireS , VanAsscheGA , RutgeertsPJ . Evolution of endoscopic activity scores under placebo therapy in Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S358. ">Ferrante 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0009" title="FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA . Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post‐hoc analysis of the sonic data. Gastroenterology2011;140(5 Suppl 1):S422. FerranteM , ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology2013;145(5):978‐86. ">Ferrante 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0010" title="GreenEH , Al‐HawaryMM , PungliaD , ZimmermannEM , AdlerJ . Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings. Gastroenterology2011;140(5 Suppl 1):S426. ">Green 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0011" title="HebuterneX , LemannM , BouhnikY , DewitO , DupasJL , MrossM , et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62(2):201‐8. HebuterneX , LemannM , Louis DupasJ , BouhnikY , AllezM , LouisE , et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study. American Journal of Gastroenterology2010;105:S418‐9. ">Hebuterne 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0012" title="JalochaL , WojtunS , GilJ , DyrlaP . Efficacy of anti‐TNF‐alpha agents in mucosal healing in Crohn disease. Przeglad Gastroenterologiczny2009;4(4):184‐7. ">Jalocha 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0013" title="JonesJ , LoftusEVJr , PanaccioneR , ChenLS , PetersonS , McConnellJ , et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clinical Gastroenterology and Hepatology2008;6(11):1218‐24. ">Jones 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0014" title="KhannaR , D’HaensG , RutgeertsP , McDonaldJ , DapernoM , FeaganB , et al. Reliability of central readers in the evaluation of endoscopic disease activity in Crohn’s disease. Inflammatory Bowel Diseases2013;19:s50. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Journal of Crohn's and Colitis2014;8:S13‐4. KhannaR , ZouG , D'HaensG , RutgeertsP , McDonaldJW , DapernoM , et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut2016;65(7):1119‐25. KhannaR , ZouG , D'HaensGR , RutgeertsPJ , McDonaldJW , DapernoM , et al. Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease. Gastroenterology2014;146(5 Suppl 1):S‐175. ">Khanna 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0015" title="Lobaton OrtegaT , Lopez‐GarciaA , Rodriguez‐MorantaF , RuizA , RodriguezL , GuardiolaJ . A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis2013;7(12):e641‐51. Lobaton OrtegaT , Rodriguez‐MorantaF , GuardiolaJ , Sanchez‐PastorE , Rodriguez AlonsoL , Ruiz‐CerullaS , et al. A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD). Journal of Crohn's and Colitis2012;6:S81. ">Lobaton Ortega 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0016" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30(7):983‐9. ">Mary 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0017" title="MolanderP , SipponenT , KemppainenH , JussilaA , BlomsterT , KoskelaR , et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha‐blocking agents in IBD. Journal of Crohn's and Colitis2013;7(9):730‐5. ">Molander 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0018" title="ReinischW , RutgeertsPJ , PanaccioneR , D'HaensGR , ThakkarR , YuAP , et al. Prediction of long‐term clinical remission for adalimumab‐treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES‐CD. Gastroenterology2010;138(5 Suppl 1):S8. ">Reinisch 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0019" title="RimolaJ , OrdasI , RodriguezS , Garcia‐BoschO , AceitunoM , LlachJ , et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflammatory Bowel Diseases2011;17(8):1759‐68. ">Rimola 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0020" title="RutgeertsP , VanAsscheG , VanDeventerS , BaoW , KeenanG , OlsonA , et al. Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease. Gastroenterology2002;122(Suppl 4):A618. ">Rutgeerts 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0021" title="RutgeertsP , DiamondRH , BalaM , OlsonA , LichtensteinGR , BaoW , et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy2006;63(3):433‐42. ">Rutgeerts 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0022" title="RutgeertsPJ , ReinischW , ThakkarR , WuEQ , KaltenboeckA , YangM , et al. Early mucosal healing status predicts long‐term clinical benefits for adalimumab‐treated patients with moderate to severe Crohn's disease. Gastroenterology2010;138(5 Suppl 1):S85. RutgeertsPJ , ThakkarR , WuEQ , KaltenboeckA , YangM , MulaniP , et al. Quality‐of‐life benefits for adalimumab‐treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status. Gastroenterology2010;138(5 Suppl 1):S320. ">Rutgeerts 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0023" title="RutgeertsP , ReinischW , ColombelJF , SandbornWJ , D'HaensG , PeterssonJ , et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy2016;83(1):188‐97. ">Rutgeerts 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0024" title="SchoepferAM , BeglingerC , StraumannA , TrummlerM , VavrickaSR , BrueggerLE , et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology2010;105(1):162‐9. ">Schoepfer 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0025" title="SipponenT , SavilahtiE , KolhoKL , NuutinenH , TurunenU , FarkkilaM . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases2008;14(1):40‐6. ">Sipponen 2008a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>excellent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0026" title="SipponenT , KarkkainenP , SavilahtiE , KolhoKL , NuutinenH , TurunenU , et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Alimentary Pharmacology and Therapeutics2008;28(10):1221‐9. ">Sipponen 2008b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0027" title="SipponenT , SavilahtiE , KarkkainenP , KolhoKL , NuutinenH , TurunenU , et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease. Inflammatory Bowel Diseases2008;14(10):1392‐8. ">Sipponen 2008c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0028" title="SipponenT , BjorkestenCG , FarkkilaM , NuutinenH , SavilahtiE , KolhoKL . Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology2010;45(3):325‐31. ">Sipponen 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0029" title="SipponenT , NuutinenH , TurunenU , FarkkilaM . Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflammatory Bowel Diseases2010;16(12):2131‐6. ">Sipponen 2010b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SES‐CD</p> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>good</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010642-bbs2-0030" title="VieiraA , FangCB , RolimEG , KlugWA , SteinwurzF , RossiniLG , et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes2009;2:221. ">Vieira 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDEIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p>CSV = construct validity</p> <p>? no information or indeterminate rating</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">The Methodological Quality of Endoscopic Index Measurement Properties as Described in the Original Development Articles (COSMIN Checklist)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010642.pub2/full#CD010642-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010642.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010642-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010642-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010642-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010642-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="pl#CD010642-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD010642-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010642-note-0013">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"/> </img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010642\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010642\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010642\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010642\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010642\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010642.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010642.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010642.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010642.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010642.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724280527"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010642.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724280531"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010642.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e5efa3f73f409',t:'MTc0MDcyNDI4MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 